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A B S T R A C T
Background
Breathlessness is a cardinal symptom of chronic obstructive pulmonary disease (COPD). Long-term oxygen therapy (LTOT) is given
to improve survival time in people with COPD and severe chronic hypoxaemia at rest. The efficacy of oxygen therapy for breathlessness
and health-related quality of life (HRQOL) in people with COPD and mild or no hypoxaemia who do not meet the criteria for LTOT
has not been established.
Objectives
To determine the efficacy of oxygen versus air in mildly hypoxaemic or non-hypoxaemic patients with COPD in terms of (1) breath-
lessness; (2) HRQOL; (3) patient preference whether to continue therapy; and (4) oxygen-related adverse events.
Search methods
We searched the Cochrane Airways Group Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and
Embase, to 12 July 2016, for randomised controlled trials (RCTs). We handsearched the reference lists of included articles.
Selection criteria
We included RCTs of the effects of non-invasive oxygen versus air on breathlessness, HRQOL or patient preference to continue therapy
among people with COPD and mild or no hypoxaemia (partial pressure of oxygen (PaO2) > 7.3 kPa) who were not already receiving
LTOT. Two review authors independently assessed articles for inclusion in the review.
Data collection and analysis
Two review authors independently collected and analysed data. We assessed risk of bias by using the Cochrane ’Risk of bias tool’. We
pooled effects recorded on different scales as standardised mean differences (SMDs) with 95% confidence intervals (CIs) using random-
effects models. Lower SMDs indicated decreased breathlessness and reduced HRQOL. We performed subanalyses and sensitivity
analyses and assessed the quality of evidence according to the Grading of Recommendations, Assessment, Development and Evaluations
(GRADE) approach.
1Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Main results
Compared with the previous review, which was published in 2011, we included 14 additional studies (493 participants), excluded one
study and included data for meta-analysis of HRQOL. In total, we included in this review 44 studies including 1195 participants, and
we included 33 of these (901 participants)in the meta-analysis.
We found that breathlessness during exercise or daily activities was reduced by oxygen compared with air (32 studies; 865 participants;
SMD -0.34, 95% CI -0.48 to -0.21; I2 = 37%; low-quality evidence). This translates to a decrease in breathlessness of about 0.7
points on a 0 to 10 numerical rating scale. In contrast, we found no effect of short-burst oxygen given before exercise (four studies;
90 participants; SMD 0.01, 95% CI -0.26 to 0.28; I2 = 0%; low-quality evidence). Oxygen reduced breathlessness measured during
exercise tests (25 studies; 442 participants; SMD -0.34, 95% CI -0.46 to -0.22; I2 = 29%; moderate-quality evidence), whereas evidence
of an effect on breathlessness measured in daily life was limited (two studies; 274 participants; SMD -0.13, 95% CI, -0.37 to 0.11; I2
= 0%; low-quality evidence).
Oxygen did not clearly affect HRQOL (five studies; 267 participants; SMD 0.10, 95% CI -0.06 to 0.26; I2 = 0%; low-quality evidence).
Patient preference and adverse events could not be analysed owing to insufficient data.
Authors’ conclusions
We are moderately confident that oxygen can relieve breathlessness when given during exercise to mildly hypoxaemic and non-
hypoxaemic people with chronic obstructive pulmonary disease who would not otherwise qualify for home oxygen therapy. Most
evidence pertains to acute effects during exercise tests, and no evidence indicates that oxygen decreases breathlessness in the daily life
setting. Findings show that oxygen does not affect health-related quality of life.
P L A I N L A N G U A G E S U M M A R Y
Oxygen therapy for breathless people with chronic obstructive pulmonary disease with only mildly or moderately decreased
oxygen in the blood
Review question
We reviewed the evidence regarding effects of oxygen compared with air on breathlessness in people with chronic obstructive pulmonary
disease (COPD) with only mildly or moderately decreased blood oxygen levels.
Background
People with COPD are sometimes prescribed oxygen therapy to reduce the severity of breathlessness. However, the use of oxygen
in people who do not have severely reduced levels of oxygen in their bloodstream remains controversial, as little is known about its
effectiveness. Additionally, oxygen is relatively costly and is not given without risk, particularly to smokers because of the risk of fire.
Study characteristics
We examined the research published to 12 July 2016. We included studies of oxygen therapy versus air delivered through nasal prongs
or mask during exertion, continuously, ’as needed’ over a defined period or as short-burst oxygen before exertion. Study participants
were 18 years of age or older, had received a diagnosis of COPD, had low oxygen levels in the blood and did not receive long-term
oxygen therapy. We included a total of 44 studies (1195 participants) in this review. Compared with the previous review, which was
published in 2011, we have added 14 studies (493 participants) to this review.
Key results
We found that oxygen can modestly reduce breathlessness. To be effective, oxygen has to be given during exercise. Most studies evaluated
oxygen given during exercise testing in the laboratory. Oxygen therapy during daily life had uncertain effects on breathlessness and did
not clearly change patient quality of life.
Quality of the evidence
We rated the quality of evidence using one of the following grades: very low, low, moderate or high. For very low-quality evidence,
we were uncertain about the results. With high-quality evidence, we were very certain about the results. We found that evidence for
oxygen given for breathlessness was moderate to low. We are moderately confident that oxygen can relieve breathlessness when given
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during exercise to people with COPD with mildly or moderately decreased blood oxygen levels. However, most studies reported acute
effects during an exercise test, and no evidence suggests that oxygen decreases breathlessness during daily life. Findings indicate that
oxygen does not affect health-related quality of life.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen
therapy
Patient or population: pat ients with chronic obstruct ive pulmonary disease who do not qualif y for home oxygen therapy
Intervention: oxygen delivered through a non-invasive method
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Health- related quality
of life - all trials
Higher scores indi-
cate improved health-
related quality of lif e
SM D 0.12, SD higher






This corresponds to 0.
25 points higher (0.09
lower to 0.59 higher) on
a 0-10 NRS.*
* Dif ference on a 0-10 NRS calculated using the SD of 2.1 for the COPD group in Abernethy 2010 for individual part icipant
data.
CI: conf idence interval; OR: odds rat io; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of ef fect.
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of
ef fect but may be substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate
of ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent
f rom the est imate of ef fect
aAlthough the ef fect was consistent in exercise tests in the laboratory sett ing, evidence of an ef fect was lim ited for domiciliary
oxygen in daily lif e.
bFew studies.
cGraded as moderate, as most evidence pertained to breathlessness during exercise tests.
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B A C K G R O U N D
Description of the condition
Breathlessness, a cardinal symptom of chronic obstructive pul-
monary disease (COPD), is distressing to both patients and care-
givers. Breathlessness is defined as “a subjective experience of
breathing discomfort that consists of qualitatively distinct sen-
sations that vary in intensity” (Parshall 2012). Breathlessness is
multi-factorial (Laviolette 2014) and arises as a combination of
underlying pathologies involving neural pathways and subjective
central perception (Parshall 2012).
Description of the intervention
Treatment of patients with breathlessness includes management of
the underlying cause(s). However, breathlessness often persists de-
spite optimal management of underlying disease(s), that is, chronic
breathlessness. Pharmacological treatment with the strongest evi-
dence base for relieving breathlessness consists of low-dose opioids
(Ekstrom 2015a). People with insufficiently relieved breathless-
ness are then left to try any of a number of interventions for which
evidence is limited, such as supplemental oxygen therapy.
Supplemental oxygen therapy most often is administered through
nasal prongs or a mask and may be prescribed continuously, dur-
ing exercise or as a short burst before exercise (Hardinge 2015).
Oxygen sources include oxygen concentrators (which concentrate
oxygen from ambient air), cylinders of compressed oxygen and
flasks of liquid oxygen. Equipment can be stationary in the home
and/or portable (Hardinge 2015).
Long-term oxygen therapy (LTOT) refers to oxygen given for 15 or
more hours per day to prolong survival time in people with COPD
and chronic severe resting hypoxaemia (partial pressure of oxygen
(PaO2) < 7.4 kPa) or moderate hypoxaemia (PaO2 7.4 to 7.8
kPa), together with signs of right-sided heart failure or secondary
polycythemia (Cranston 2005; MRCWP 1981; NOTTG 1980).
Studies in severe hypoxaemia have not evaluated whether LTOT
relieves breathlessness or improves health-related quality of life
(HRQOL) (Cranston 2008).
Palliative oxygen therapy refers to supplemental oxygen given to
relieve symptoms in people with COPD who have no to moderate
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hypoxaemia.
How the intervention might work
Oxygen given before or during physical activity might increase
oxygen content of and oxygen delivery to exercising muscles. This
might prolong aerobic metabolism during exertion and may de-
crease muscle fatigue and formation of lactic acid (O’Donnell
2001), which could lead to a decreased level of ventilatory drive
and increased ventilatory capacity at a given work rate, thereby de-
creasing the mismatch between ventilatory drive and work and per-
ceived severity of breathlessness (O’Donnell 2001; Parshall 2012).
Why it is important to do this review
A Cochrane review of the efficacy of palliative oxygen for breath-
lessness was published in 2011 (Uronis 2011; Uronis 2015). A
meta-analysis of 18 trials (431 participants) reported that supple-
mental oxygen during exercise and activities reduced breathless-
ness to a greater extent than air. Short-burst oxygen before ex-
ercise did not decrease breathlessness. Review authors could not
analyse HRQOL because data were insufficient. Most evidence
pertained to exercise testing performed in the laboratory setting
(Uronis 2011; Uronis 2015). A subsequent Cochrane review of
four studies (331 participants) suggested that longer-term treat-
ment with ambulatory oxygen relieves breathlessness more effec-
tively than air after exercise in people with COPD (Ameer 2014).
Current guidelines do not recommend palliative oxygen therapy
in COPD, as evidence on treatment in the domiciliary and daily
life setting remains insufficient (Ekstrom 2015b; Hardinge 2015).
Despite this, palliative oxygen therapy might be commonly pre-
scribed in clinical practice (Abernethy 2005; Stringer 2004).
The discrepancy between current clinical practice and available
evidence has important implications. First, patients may be pre-
scribed ineffective treatment. Second, oxygen therapy is not a be-
nign intervention. Functional restriction caused by tubing, con-
centrators or cylinders and the “sick role” may limit quality of
life. People also express concern about being reliant on a machine.
Nasal cannulae can lead to nasal irritation and can increase the risk
of nosebleeds. Oxygen therapy carries a fire risk, particularly for
smokers (Robb 2003). Serious burn injuries seem infrequent in
LTOT with strict adherence to eligibility criteria and contraindi-
cations, including smoking cessation (Tanash 2015). A small but
increased risk of exacerbated hypercarbia is possible, and home
oxygen therapy is relatively expensive. If patients do not meet the
criteria for LTOT, they may have to pay for oxygen therapy them-
selves or may receive it on compassionate use grounds (Guyatt
2000). Improved evidence regarding optimal use of palliative oxy-
gen therapy is needed.
Since the previous Cochrane reviews were published (Uronis 2011;
Uronis 2015), several studies of palliative oxygen therapy have
been reported, including some larger trials (Abernethy 2010 and
Moore 2011).
This is an update of the Cochrane review published in 2011 (
Uronis 2011; Uronis 2015).
O B J E C T I V E S
To determine the efficacy of oxygen versus air in mildly hypox-
aemic or non-hypoxaemic patients with COPD in terms of (1)
breathlessness; (2) HRQOL; (3) patient preference whether to
continue therapy; and (4) oxygen-related adverse events.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs).
Types of participants
We included studies with participants 18 years of age or older who
had COPD, had mild or no hypoxaemia (mean PaO2 > 7.3 kPa)
and did not receive LTOT. For studies that also included partici-
pants without COPD, we obtained from study authors individual
participant data for those with COPD and included only these
data in the analyses.
Types of interventions
We included studies of oxygen therapy versus air delivered by a
non-invasive method at any inspired dose above that of ambient air
(> 21%). Oxygen/air should have been delivered during exertion,
continuously or ’as needed’ over a defined period, or as short-burst
oxygen before exertion. Short-burst oxygen was defined as therapy
given during a short, defined period just before exertion. We did
not include short-burst oxygen given only after exertion.
Types of outcome measures
Primary outcomes
1. Level of breathlessness measured on any validated scale
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Secondary outcomes
1. HRQOL measured on any validated scale
2. Blinded participant preference to continue therapy
3. Adverse events
Search methods for identification of studies
Electronic searches
We searched the Cochrane Airways Group Specialised Register of
trials, which is derived from systematic searches of multiple biblio-
graphic databases and from handsearching of respiratory journals
and meeting abstracts (see Appendix 1 for details). We conducted
additional searches of the Cochrane Central Register of Con-
trolled Trials (CENTRAL; 2016, Issue 6), MEDLINE (to 12 July
2016) and Embase (to 12 July 2016). Search strategies are shown
in Appendix 2; Appendix 3; Appendix 4; and Appendix 5. We
also searched ClinicalTrials.gov (www.ClinicalTrials.gov) and the
World Health Organization (WHO) trials portal (www.who.int/
ictrp/en/) for ongoing trials by using appropriately adapted search
terms. We searched all databases from their inception to 12 July
2016, with no restriction on language of publication.
Searching other resources
We handsearched relevant review articles and reference lists of
identified articles.
Data collection and analysis
Selection of studies
Two review authors (ME and ZA) independently selected studies
that fulfilled all inclusion criteria.
1. RCT.
2. Included participants 18 years of age or older.
3. At least one participant with COPD.
4. Mean PaO2 > 7.3 kPa at baseline.
5. Only participants not already receiving LTOT.
6. Comparison of oxygen versus air at any dose delivered
through a non-invasive method.
7. Endpoint of breathlessness or HRQOL.
Data extraction and management
Two review authors (ME and ZA) independently extracted data
and resolved disagreements by consensus and discussion with a
third review author (DC), if needed. We contacted the authors of
primary studies to obtain additional information when necessary.
Assessment of risk of bias in included studies
Two review authors (ME and ZA) independently assessed each
study for risk of bias in terms of allocation sequence generation,
allocation concealment, blinding of participants and outcome as-
sessors, handling of missing data, selective outcome reporting and
other threats to the validity of studies, in line with recommenda-
tions provided in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). We conducted a retrospective risk
of bias assessment using the above method applied to all studies
from the review published in 2011 (Uronis 2011).
Measures of treatment effect
We performed meta-analyses as appropriate and possible, given
available data. We analysed outcomes on different scales as stan-
dardised mean differences (SMDs) using random-effects models.
We compared within-patient effects from both periods of cross-
over trials. Meta-analyses included post scores only. For studies for
which post scores were not available, we reported changes from
baseline scores separately. For breathlessness during exercise, we
used scores measured at a similar time point in both groups (iso-
scores) when available. For studies evaluating different oxygen
doses, we included only the lowest dose in the analysis. We reversed
St George’s Respiratory Quotient (SGRQ) scores (as increasing
scores indicate worse quality of life), so that higher scores on all
HRQOL measures indicated better quality of life in all analyses.
Unit of analysis issues
We estimated standard errors for paired outcome data from cross-
over trials, according to Follmann 1992. We estimated correlations
between repeated outcomes from P values when available, and
for studies for which little evidence was available to impute a
correlation coefficient from another trial, we assumed a value of
0.5 (Follmann 1992). We performed sensitivity analyses using
different imputed correlations.
Dealing with missing data
When statistics essential for analysis were missing (e.g. group
means and standard deviations for both groups were not reported)
and could not be calculated from other data, we attempted to con-
tact study authors to obtain the missing data. We assumed that
loss of participants that occurred before baseline measurements
were taken had no effect on eventual outcome data provided by
the study. We assessed any losses that occurred after baseline mea-
surements had been taken and discussed them on an intention-to-
treat basis.
Assessment of heterogeneity
We assessed statistical heterogeneity by using the I² statistic and
by inspecting funnel plots.
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Assessment of reporting biases
We assessed possible publication bias by using funnel plots.
Data synthesis
We performed meta-analyses by using Review Manager software
version 5.3 (RevMan 2014).
Subgroup analysis and investigation of heterogeneity
We conducted the following a priori subgroup analyses on the
presence/absence of:
1. short-burst oxygen therapy;
2. exertional desaturation (oxygen saturation (SaO2) < 88% as
entry criteria, or mean PaO2 < 8 kPa on exertion);
3. baseline mean PaO2 breathing air < 9.3 kPa;
4. measurement during exertion;
5. laboratory setting (compared with domiciliary setting);
6. measured acute oxygen effect (test on oxygen vs air)
compared with long-term oxygen effect (test on the same inhaled
gas after a period of oxygen or air); and
7. mean oxygen dose > 2 L/min. For studies that reported only
administered fraction of inspired oxygen (FiO2), an oxygen dose
> 2 L/min was defined as FiO2 > 0.27.
Sensitivity analysis
We conducted the following a priori sensitivity analyses by exclud-
ing studies with:
1. measurement at peak exertion (compared with iso-time);
2. high risk of bias for any bias category;
3. any participant without COPD; and
4. outlier findings (based on forest and funnel plots).
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies tables.
Participant characteristics
All 1195 participants included in the analysis had COPD (Table
1). Baseline PaO2 was provided in 30 of 44 studies, ranging from
7.7 to 11.3 kPa. Twelve of the remaining studies provided baseline
oxygen saturation ranging from 90% to 97% (Table 1).
Twenty studies reported mean baseline breathlessness at rest as
follows: visual analogue score (VAS) score 5 to 40 mm (100 mm
VAS); Borg score 0.1 to 1 point (Table 1).
Intervention characteristics
All studies compared oxygen versus air, delivered via the same non-
invasive method in both groups. The most frequent mode of ad-
ministration was the nasal cannula (22 studies) (Abernethy 2010;
Davidson 1988; Dyer 2012; Eaton 2002; Eaton 2006; Haidl 2004;
Jolly 2001a; Jolly 2001b; Knebel 2000; Kurihara 1989; Lewis
2003; McDonald 1995; McKeon 1988a; McKeon 1988b; Moore
2011; Nonoyama 2007; Ringbaek 2013; Rooyackers 1997a;
Rooyackers 1997b; Spielmanns 2014; Wadell 2001; Woodcock
1981) followed by mouthpiece/valve (13 studies) (Bruni 2012a;
Bruni 2012b; Dean 1992; Emtner 2003a; Emtner 2003b; Eves
2006; Laude 2006; Maltais 2001; Moore 2009; O’Donnell 1997;
Scorsone 2010; Somfay 2001; Swinburn 1984) and mask (eight
studies) (Killen 2000; Leach 1992; Miki 2012: Nandi 2003;
O’Driscoll 2011; Oliveira 2012a; Oliveira 2012b; Voduc 2010)
or unknown (one study) (Ishimine 1995).
Doses of oxygen provided ranged from 2 to 6 L/min via nasal
cannula, and FiO2 ranged from 24% to 75% via mask/mouthpiece
(Table 1).
A total of 32 studies (Bruni 2012a; Bruni 2012b; Davidson 1988;
Dean 1992; Eaton 2006; Emtner 2003a; Emtner 2003b; Eves
2006; Haidl 2004; Ishimine 1995; Jolly 2001a; Jolly 2001b;
Killen 2000; Knebel 2000; Kurihara 1989; Laude 2006; Leach
1992; Maltais 2001; McKeon 1988b; Miki 2012; O’Donnell
1997; Oliveira 2012a; Oliveira 2012b; Rooyackers 1997a;
Rooyackers 1997b; Scorsone 2010; Somfay 2001; Spielmanns
2014; Swinburn 1984; Voduc 2010; Wadell 2001; Woodcock
1981) provided continuous oxygen during exercise testing - six-
minute walk test (6MWT), endurance shuttle walk test, incre-
mental shuttle walk test, step test or cycle exercise test. .
Six studies (Abernethy 2010; Eaton 2002; McDonald 1995;
Moore 2011; Nonoyama 2007; Ringbaek 2013) provided domi-
ciliary oxygen during daily life and activities.
Four studies (Killen 2000; Lewis 2003; McKeon 1988a; Nandi




Twenty-nine studies (Bruni 2012a; Bruni 2012b; Dean 1992;
Eaton 2002; Emtner 2003a; Emtner 2003b; Eves 2006; Haidl
2004; Jolly 2001a; Jolly 2001b; Kurihara 1989; Laude 2006;
Lewis 2003; Maltais 2001; McDonald 1995; Miki 2012; Moore
2009; Nonoyama 2007; O’Donnell 1997; O’Driscoll 2011;
Oliveira 2012a; Oliveira 2012b; Ringbaek 2013; Rooyackers
1997a; Rooyackers 1997b; Scorsone 2010; Somfay 2001; Voduc
2010; Wadell 2001) measured breathlessness using a modified
Borg scale, nine studies (Davidson 1988; Killen 2000; Knebel
2000; Leach 1992; McKeon 1988a; McKeon 1988b; Nandi 2003;
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Swinburn 1984; Woodcock 1981) used a VAS and five studies
(Abernethy 2010; Dyer 2012; Eaton 2006; Ishimine 1995; Moore
2011) used other scales (Table 1).
HRQOL
Seven studies (Eaton 2002; Eaton 2006; Emtner 2003a; Emtner
2003b; Moore 2011; Rooyackers 1997a; Rooyackers 1997b) mea-
sured HRQOL as Chronic Respiratory Questionnaire (CRQ) to-
tal score, 10 studies (Dyer 2012; Eaton 2002; Eaton 2006; Emtner
2003a; Emtner 2003b; McDonald 1995; Moore 2011; Nonoyama
2007; Rooyackers 1997a; Rooyackers 1997b) as CRQ subdo-
mains, five studies (Eaton 2002; Eaton 2006; Emtner 2003a;
Emtner 2003b; Spielmanns 2014) as Short Form-36 (SF-36) to-
tal score and two studies (Nonoyama 2007; Ringbaek 2013) as
SGRQ total score. One study (Abernethy 2010) measured per-
ceived overall well-being on a 0 to 10 VAS and HRQOL over
weeks or months (Table 1), with higher scores indicating better
HRQOL.
Results of the search
Of an identified 866 unique records, we included 44 studies (1195
participants) in this update review (Figure 1). Compared with the
previous review, which was published in 2011 (Uronis 2011), we
included 14 additional studies (Abernethy 2010; Bruni 2012a;
Bruni 2012b; Dyer 2012; Miki 2012; Moore 2011; Nonoyama
2007; O’Driscoll 2011; Oliveira 2012a; Oliveira 2012b; Ringbaek
2013; Scorsone 2010; Spielmanns 2014; Voduc 2010), and we
excluded one additional trial (Garrod 2000).
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Figure 1. Study flow diagram.
10Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Included studies
We have provided characteristics of the 44 included studies in
the Characteristics of included studies table and in Table 1.
Of 44 included studies, 31 were cross-over trials (Bruni 2012a;
Bruni 2012b; Davidson 1988; Dean 1992; Eaton 2002; Eves
2006; Ishimine 1995; Jolly 2001a; Jolly 2001b; Killen 2000;
Knebel 2000; Kurihara 1989; Laude 2006; Leach 1992; Lewis
2003; Maltais 2001; McDonald 1995; McKeon 1988a; McKeon
1988b; Miki 2012; Moore 2009; Nandi 2003; Nonoyama 2007;
O’Donnell 1997; O’Driscoll 2011; Oliveira 2012a; Oliveira
2012b; Somfay 2001; Swinburn 1984; Voduc 2010; Woodcock
1981) and 13 were parallel-group trials (Abernethy 2010; Dyer
2012; Eaton 2006; Emtner 2003a; Emtner 2003b; Haidl 2004;
Moore 2011; Ringbaek 2013; Rooyackers 1997a; Rooyackers
1997b; Scorsone 2010; Spielmanns 2014; Wadell 2001).
Ten studies (Bruni 2012a; Bruni 2012b; Emtner 2003a; Emtner
2003b; Jolly 2001a; Jolly 2001b; Oliveira 2012a; Oliveira 2012b;
Rooyackers 1997a; Rooyackers 1997b) included two different
comparisons of independent groups, which we included in the
analysis.
Excluded studies
We have presented excluded trials with reasons for exclusion in the
Characteristics of excluded studies table. We identified two ongo-
ing or recently completed trials but did not include them in this
review, as data were unavailable: the Long-Term Oxygen Therapy
Trial (LOTT; registered at ClinicalTrials.gov: NCT00692198) of
supplemental oxygen in 738 participants with COPD and moder-
ate hypoxaemia at rest and/or exertion, which included measures
of breathlessness and HRQOL; and another recently completed
cross-over study comparing effects of supplemental oxygen versus
air on breathlessness during exercise testing in 11 participants with
COPD, which was presented as an abstract (Vesteng 2015).
Risk of bias in included studies
We have provided risk of bias judgements for each study at the
end of each Characteristics of included studies table and have
summarised each risk of bias category in Figure 2. Methods were
poorly reported in most of the included studies. We assessed risk of
bias as mostly unclear regarding selection bias, but as low for more
than half of studies regarding performance, detection, attrition
and reporting bias, and as mostly unclear regarding other biases
(Figure 2).
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
Although all studies were described as randomised, we could
verify that sequence generation was adequate in only 11 stud-
ies (Abernethy 2010; Dyer 2012; Eaton 2006; Emtner 2003a;
Emtner 2003b; Moore 2011; Nonoyama 2007; O’Driscoll 2011;
Ringbaek 2013; Spielmanns 2014; Wadell 2001). Concealment
of allocation was adequate in 10 studies and inadequate in three
studies (Figure 2). For remaining studies, we had insufficient in-
formation to determine risk of bias for allocation procedures.
Blinding
Masking of treatment was undertaken in several studies. For five
studies, we were unable to determine how blinding of study par-
ticipants or investigators had been achieved. For 12 studies (Haidl
2004; Killen 2000; Kurihara 1989; Leach 1992; Lewis 2003;
O’Driscoll 2011; Ringbaek 2013; Rooyackers 1997a; Rooyackers
1997b; Somfay 2001; Swinburn 1984; Wadell 2001), we found
that blinding was not undertaken, or investigators knew which
containers contained oxygen. The remaining 27 studies attempted
blinding of both study participants and study investigators (Figure
2).
Incomplete outcome data
Twenty-six studies (Bruni 2012a; Bruni 2012b; Dean 1992;
Eaton 2002; Emtner 2003a; Emtner 2003b; Eves 2006; Jolly
2001a; Jolly 2001b; Killen 2000; Leach 1992; Maltais 2001;
McKeon 1988a; McKeon 1988b; Moore 2009; Moore 2011;
Nandi 2003; O’Donnell 1997; Oliveira 2012a; Oliveira 2012b:
Rooyackers 1997a; Rooyackers 1997b; Scorsone 2010; Somfay
2001; Swinburn 1984; Woodcock 1981) reported no withdrawals.
Cross-over studies analyse within-participant differences; there-
fore, participants who did not complete both treatment periods
were not included in the analyses. For the remaining studies, we
could not reliably ascertain how missing data were handled (Figure
2).
Selective reporting
Possible publication bias on the effect of oxygen on breathlessness
was indicated by the funnel plot shown in Figure 3. Studies show-
ing a larger positive effect of oxygen on breathlessness were more
likely to have lower precision. Asymmetry was apparent, with few
studies with low precision reporting no or non-beneficial effects
of oxygen on breathlessness (Figure 3).
Figure 3. Funnel plot of comparison: 1 Oxygen versus air, outcome: 1.1 Breathlessness - all trials.
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Other potential sources of bias
We categorised the risk of other sources of bias as high for Dyer
2012 and as unclear for most studies.
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings table
All comparisons consisted of oxygen versus air delivered by the
same mechanism among participants with COPD and no or mild
hypoxaemia.
Primary outcome: breathlessness
The meta-analysis of breathlessness included 32 studies with
865 participants (Abernethy 2010; Bruni 2012a; Bruni 2012b;
Davidson 1988; Dean 1992; Eaton 2002; Emtner 2003a; Emtner
2003b; Eves 2006; Jolly 2001a; Jolly 2001b; Killen 2000; Knebel
2000; Kurihara 1989; Laude 2006; Lewis 2003; McDonald
1995; McKeon 1988a; Miki 2012; Moore 2011; Nandi 2003;
Nonoyama 2007; O’Donnell 1997; Oliveira 2012a; Oliveira
2012b; Ringbaek 2013; Rooyackers 1997a; Rooyackers 1997b;
Scorsone 2010; Somfay 2001; Voduc 2010; Woodcock 1981).
In pooled analysis of all trials, we found that oxygen reduced
breathlessness (SMD -0.31, 95% CI -0.43 to -0.20; I2 = 29%;
Analysis 1.1; low-quality evidence).
A priori subgroup analyses of breathlessness
Short-burst oxygen therapy
Short-burst oxygen therapy before exertion did not reduce breath-
lessness (SMD -0.03, 95% CI -0.28 to 0.22; four studies; I2 =
0%), whereas oxygen given during exercise or daily activities did
reduce breathlessness (SMD -0.36, 95% CI -0.48 to -0.24; 28
studies; I2 = 27%; Analysis 1.2; low-quality evidence). Differences
between groups were statistically significant (P = 0.02).
Exertional desaturation
In studies with desaturation during exercise, defined as SaO2 <
88% among entry criteria or mean PaO2 < 8 kPa on exertion,
oxygen reduced breathlessness (SMD -0.28, 95% CI -0.39 to -
0.16; 16 studies), but the effect tended to be greater in studies
without exertional desaturation (SMD -0.47, 95% CI -0.69 to -
0.24; 15 studies; Analysis 1.3). P = 0.14 for differences between
groups.
Baseline mean PaO2 (air) < 9.3 kPa
The effect of oxygen was similar among studies with baseline mean
PaO2 (air) < 9.3 kPa (SMD -0.28, 95% CI -0.48 to -0.07; seven
studies) and studies with PaO2 (air) ≥ 9.3 kPa (SMD -0.33, 95%
CI -0.47 to -0.20; 25 studies; Analysis 1.4), as shown in Figure 4.
P = 0.65 for differences between groups.
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Figure 4. Forest plot of comparison: 1 Oxygen versus air, outcome: 1.2 Breathlessness - subgroup analysis -
short-burst oxygen versus not.
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Measurement during exercise test
Most studies measured breathlessness during exertion (SMD -
0.34, 95% CI -0.46 to -0.22; 30 studies); only two studies mea-
sured breathlessness in daily life and found a smaller and less pre-
cise effect of oxygen (SMD -0.13, 95% CI -0.37 to 0.11; two stud-
ies; Analysis 1.5; moderate-quality evidence), as shown in Figure
5. P = 0.12 for differences between groups.
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Figure 5. Forest plot of comparison: 1 Oxygen versus air, outcome: 1.5 Breathlessness - subgroup analysis -
measured during exercise test versus not.
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Laboratory setting
Most studies measured breathlessness during exercise testing in a
laboratory setting (SMD -0.37, 95% CI -0.52 to -0.22; 25 studies).
The effect of oxygen was less in non-laboratory domiciliary settings
(SMD -0.23, 95% CI -0.36 to -0.09; seven studies; Analysis 1.6).
P = 0.16 for differences between groups.
Short-term versus long-term (training) oxygen effects
Most studies evaluated acute effects of oxygen by comparing an
exercise test on oxygen versus an exercise test on air (SMD -0.34,
95% CI -0.46 to -0.22; 29 studies). Investigators evaluated a po-
tential longer-term (training) effect of oxygen by performing a test
on the same gas after a (training) period with oxygen or air. Only
three studies performed this evaluation and found no evidence
of a long-term effect of oxygen (SMD -0.09, 95% CI -0.37 to
0.19; three studies; Analysis 1.7). P = 0.11 for differences between
groups.
Mean oxygen dose > 2 L/min
Most studies evaluated oxygen at a dose > 2 L/min, which tended
to reduce breathlessness more (SMD -0.35, 95% CI -0.49 to -
0.21; 25 studies) than an oxygen dose ≤ 2 L/min (SMD -0.19,
95% CI -0.39 to 0.01; five studies; Analysis 1.8). P = 0.19 for
differences between groups.
A priori sensitivity analyses of breathlessness
Analysis excluding trials measuring breathlessness at peak
exertion
Oxygen reduced breathlessness measured at iso-time (SMD -0.37,
95% CI -0.50 to -0.24; 26 studies; I2 = 32%) but had no effect on
breathlessness measured at peak exertion (SMD -0.14, 95% CI -
0.33 to 0.05; six studies; I2 = 0%; Analysis 1.9).
Analysis excluding trials with high risk of bias
When we excluded trials with high risk of bias for any bias cat-
egory (risk of bias shown in Figure 2), the effect of oxygen on
breathlessness remained unchanged (SMD -0.30, 95% CI -0.41
to -0.20; 25 studies; I2 = 14%; Analysis 1.10).
Analysis excluding trials with any participant without COPD
All participants included in the meta-analysis had COPD. For
studies that included non-COPD participants, we used individual
participant data for the COPD subgroup (Abernethy 2010).
Analysis excluding outlier findings
Upon inspecting forest and funnel plots (Figure 3; Figure 4), we
identified five outlier findings (Bruni 2012a; Bruni 2012b; Dean
1992; Jolly 2001a; Jolly 2001b; Somfay 2001). Exclusion of the
outliers revealed that oxygen reduced breathlessness, but the effect
became slightly smaller (SMD -0.27, 95% CI -0.35 to -0.18; 26
studies; I2 = 0%; Analysis 1.11). The effect of continuous oxygen
during exertion or daily activities (no short-burst therapy) was
similar after outliers were excluded (SMD -0.30, 95% CI -0.39 to
-0.20; 22 studies; I2 = 0%; Analysis 1.12).
Secondary outcome: HRQOL
Meta-analysis
Twelve studies (Abernethy 2010; Dyer 2012; Eaton 2002; Eaton
2006; Emtner 2003a; Emtner 2003b; McDonald 1995; Moore
2011; Nonoyama 2007; Ringbaek 2013; Rooyackers 1997;
Spielmanns 2014) examined changes in HRQOL. Of these, we
were able to include five studies (267 participants) (Eaton 2002;
Moore 2011; Nonoyama 2007; Rooyackers 1997; Spielmanns
2014) in the meta-analysis. Oxygen had no clear effect on
HRQOL (SMD 0.12, 95% CI -0.04 to 0.28; five studies; I2 =
0%; Analysis 1.13; low-quality evidence), as shown in Figure 6.
In the analysis, higher scores indicated better HRQOL.
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Figure 6. Forest plot of comparison: 1 Oxygen versus air, outcome: 1.13 Health-related quality of life - all
trials.
Descriptive analysis of studies not included in meta-analysis
We did not include seven studies in the meta-analysis, as they did
not use a validated scale of HRQOL (Abernethy 2010), reported
only HRQOL subdomain scores (Dyer 2012; McDonald 1995),
reported change scores (Emtner 2003a; Emtner 2003b; Ringbaek
2013) or provided data that could not be combined in the analysis
(Eaton 2006). For all scales used, higher scores indicated better
quality of life.
Abernethy 2010 measured overall perceived quality of life over the
past two days on a 0 to 10 numerical rating scale (NRS) based on
a daily diary kept over seven days. In the subgroup with COPD
(n = 158), improvement from baseline at day 7 was 0.8 points
(standard deviation (SD) 2.0) in the oxygen group and 0.3 points
(SD 1.9) in the air group.
Dyer 2012 measured change from baseline in CRQ subdomain
scores after six to seven weeks of pulmonary rehabilitation using
oxygen or air. The only statistically and clinically significant change
was found in the CRQ mastery score. For oxygen compared with
air, the mean difference was -0.1 (95% CI -0.9 to 0.7; P = 0.76)
for the domain CRQ breathlessness, 0.5 (95% CI -0.2 to 1.2; P =
0.15) for CRQ emotion, 0.7 (95% CI -0.1 to 1.5; P = 0.10) for
CRQ fatigue and 0.7 (95% CI 0.0 to 1.4; P = 0.006) for CRQ
mastery scores.
Eaton 2006 was a randomised, controlled, parallel-group trial that
included three arms as follows: oxygen, air and usual care. The only
domain of the CRQ to show statistical significance (P = 0.045)
was emotional function; the greatest improvement was noted in
the usual care group, which received neither oxygen nor air.
For Emtner 2003a and Emtner 2003b, CRQ total score and sub-
scores increased significantly in both groups. Only in mastery was
a statistically significantly greater improvement detected in the
oxygen-trained group (P < 0.05). For the Short Form-36, a signif-
icant difference (improvement) in general health was seen in the
oxygen compared with the air group (P < 0.05).
McDonald 1995 measured subdomains of CRQ and noted sta-
tistically significant improvement in all CRQ subdomains for the
comparison of baseline scores versus scores after six weeks of oxy-
gen therapy (P < 0.02 for all domains). However, when scores after
oxygen therapy were compared with scores after air, they reported
no statistically or clinically significant differences.
Ringbaek 2013 measured total SGRQ score at 7 weeks compared
with baseline. Mean changes from baseline were -1.8 (SD 8) for
the oxygen group and -3.2 (SD 7.2) for no oxygen group; the
difference between groups was not statistically significant (P =
0.80).
Secondary outcome: blinded patient preference
Five studies (Abernethy 2010; Eaton 2002; Killen 2000;
McDonald 1995; Moore 2011) assessed patient preference to con-
tinue therapy (oxygen vs air delivered by the same mechanism) at a
time when participants were still blinded. Owing to heterogeneity
of the reported data, we could not perform a meta-analysis.
Abernethy 2010 assessed patient preference after seven days of
blinded oxygen/air by asking the question, “Reviewing the ben-
efits and burdens of your experience with the treatment over the
past week, would you want to continue this treatment?” Among
participants with COPD who answered (N = 139), preferences
to continue treatment were as follows in the oxygen group: yes
50%, maybe 27% and no 23%. In the air group, preferences were
yes 41%, maybe 23% and no 36%. The difference in preference
between groups was not statistically significant (P = 0.25).
Eaton 2002 asked participants (N = 41) if they were interested
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in clinical provision of oxygen at study completion. Among par-
ticipants identified as having a short-term response to oxygen, 14
participants did not wish to be considered for continued therapy.
Eleven of these 14 (76%) cited poor tolerability or acceptability
as the reason.
Killen 2000 studied short-burst oxygen given immediately before
and after walking up a flight of steps, asking participants which
blinded gas they preferred. Of 18 participants, five preferred oxy-
gen before ascending the stairs, three preferred air and three had
no preference. The remaining seven participants preferred to re-
ceive oxygen at the top of the stairs. As a group, participants ex-
pressed no statistically significant preference for oxygen therapy
(P = 0.12).
McDonald 1995 included both acute assessments and a domicil-
iary portion that lasted six weeks with each gas, asking partici-
pants (N = 26) at the end of the study which six-week period they
preferred. Fifty percent preferred the period when they received
oxygen; the remaining 50% preferred air or had no preference.
Moore 2011 asked participants whether they wanted to continue
or discontinue the provision of domiciliary cylinders after the 12-
week study period. Preferences were similar between groups; 35
of 65 (54%) wanted to continue in the oxygen group compared
with 37 of 73 (51%) in the air group.
Secondary outcome: adverse events
Adverse events were insufficiently and inconsistently reported;
therefore, meta-analysis was not possible.
Abernethy 2010 included a total of 65 participants in the oxygen
group and 70 in the air group. Serious adverse events were rare,
with no clinically meaningful differences between groups for mod-
erate to extreme drowsiness (47% oxygen vs 51% air); moderate
to extreme nasal irritation (29% oxygen vs 35% air); moderately
to extremely troublesome nosebleeds (3% oxygen vs 3% air) and
moderate to extreme anxiousness (26% oxygen vs 40% air).
Dyer 2012 included a total of 47 participants in the study. In-
vestigators reported seven dropouts; three participants withdrew
because of an exacerbation of their condition, one because of other
medical problems and three for social reasons.
Eaton 2002 included a total of 41 participants in the study. Inves-
tigators reported nine dropouts; causes of dropout included mor-
bidity for two participants and cancer for one participant in both
study groups. Three in each group withdrew for personal reasons.
Eaton 2006 included a total of 25 participants in the oxygen group
and 26 in the air group. Five participants in the oxygen group
died, one was admitted to the hospital and three were prescribed
LTOT. In the air group, two participants died, one was prescribed
LTOT, one was admitted to a rest home and four were admitted
to the hospital.
Emtner 2003a and Emtner 2003b included a total of 14 partici-
pants in the oxygen group and 15 in the air group. We excluded
one participant from the oxygen-trained group because of illness
post intervention.
Haidl 2004 included a total of 26 participants in the study. During
three-year follow-up, four participants in the oxygen group died
and one was given a diagnosis of cancer.
Knebel 2000 included a total of 31 participants in the study. Two
participants were unable to complete all of the walks in the study
because of unrelated problems (fever and migraine headache).
Laude 2006 included a total of 76 participants in the study. After
randomisation, seven participants withdrew: five because of exac-
erbations and two for other reasons.
Lewis 2003 included a total of 18 participants in the study and
reported four dropouts. Two participants failed to complete the
first visit and attend the second visit (chest pain during 6MWT
(n = 1), personal reasons (n = 1)). Furthermore, two participants
failed to attend the second visit (clinically unstable (n = 1), other
(n = 1)).
McDonald 1995 included a total of 26 participants in the study
and reported seven dropouts; three participants withdrew during
the first six weeks of domiciliary therapy (acute gout, muscular pain
related to pulling the gas cylinder, unwillingness to continue in the
study, respectively), each of whom had received cylinder air in the
first six weeks. A total of four participants were withdrawn during
the second six weeks: One participant died of a cerebrovascular
accident and another of overwhelming pneumonia, a third was
hospitalised with an acute exacerbation of COPD and the last
incurred an incidental injury. All four participants had received
cylinder oxygen during this second six-week trial period.
Moore 2011 included a total of 66 participants in the oxygen
group and 73 in the air group. After randomisation, among those
allocated to cylinder oxygen, one participant was deceased and one
got unwell.
Nonoyama 2007 included a total of 27 participants in the study
and reported 11 dropouts. Five were reluctant to continue, three
developed resting hypoxaemia with a PaO2 less than 55 mmHg,
two died, and one was non-compliant, utilising the test mixtures
for less than one hour per day.
Ringbaek 2013 included a total of 15 participants in the oxygen
group and 22 in the air group. At study end (33 weeks), the mean
number of adverse events did not differ significantly between treat-
ment groups in terms of acute COPD exacerbations (P = 0.30) or
number of participants with hospital admission or dropout (P =
0.59).
Spielmanns 2014 included a total of 19 participants in the oxygen
group and 17 in the air group. After randomisation, in the oxygen
group, five participants discontinued owing to comorbidities, and
in the air group, seven discontinued because of comorbidities.
Voduc 2010 included a total of 15 participants in the study. After
randomisation, three participants developed COPD exacerbations
and one developed worsening of arthritis that limited exercise and
thus was excluded.
Bruni 2012a; Bruni 2012b; Davidson 1988; Dean 1992;
Eves 2006; Ishimine 1995; Jolly 2001a; Jolly 2001b; Killen
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2000; Kurihara 1989; Leach 1992; Maltais 2001; McKeon
1988a; McKeon 1988b; Miki 2012; Moore 2009; Nandi 2003;
O’Donnell 1997; O’Driscoll 2011; Oliveira 2012a; Oliveira
2012b; Rooyackers 1997a; Rooyackers 1997b; Scorsone 2010;
Somfay 2001; Swinburn 1984; Wadell 2001; and Woodcock 1981
did not report adverse events.
D I S C U S S I O N
Summary of main results
Since the previous version of this review was published in 2011
(Uronis 2011), we have included an additional 14 studies of the
effects of oxygen versus air on breathlessness, we have excluded
one study, and data for meta-analysis of health-related quality of
life (HRQOL) are now available.
When compared with air, continuous oxygen (not short-burst oxy-
gen) reduced breathlessness more during exercise or activity (stan-
dard mean difference (SMD) -0.36, 95% confidence interval (CI)
-0.48 to -0.24), and most data pertaining to breathlessness were
obtained during exercise testing in the laboratory setting. This ef-
fect translated to a mean decrease in breathlessness of 0.7 points
on a 0 to 10 numerical rating scale (NRS) based on data from a
recent large study (Abernethy 2010). The minimal clinically im-
portant difference in chronic breathlessness has been reported to
be 1 point, with small, moderate and large effects seen at about
0.6, 1.1 and 1.8 points, respectively (Johnson 2013). It is unclear
whether the effect of oxygen on breathlessness could be clinically
meaningful for many participants in this setting.
Evidence for breathlessness pertains mostly to acute effects of ex-
ercise testing on breathlessness in the laboratory setting. Effects on
breathlessness during daily life (not measured during an exercise
test) in the domiciliary setting were smaller and were statistically
non-significant (SMD -0.13, 95% CI -0.37 to 0.11).
Short-burst oxygen therapy before exertion did not affect breath-
lessness.
Oxygen did not clearly affect HRQOL (SMD 0.10, 95% CI -0.06
to 0.26). Blinded patient preference to continue therapy did not
differ between groups given oxygen and groups given air. Inves-
tigators insufficiently reported adverse events, and we could not
meta-analyse adverse event data.
Overall completeness and applicability of
evidence
After an extensive database and literature search, we included 44
studies (1195 participants) in this update review. Although two
relatively large studies of ambulatory oxygen have been published
in recent years (Abernethy 2010; Moore 2011), additional high-
quality data on effects of ambulatory oxygen in daily life, includ-
ing effects on HRQOL, are needed. Good methodological rigour
would include publication of a prespecified protocol outlining
trial design, adequate sequence generation, randomisation, blind-
ing (for participants and for outcome assessors) and transparent
reporting of appropriate outcomes at baseline in a format suitable
for meta-analysis (e.g. mean with standard deviation and sample
size).
Mechanism of effect on breathlessness
The likely mechanism underpinning an effect on breathlessness is
that supplemental oxygen prevents or decreases hypoxaemia dur-
ing exercise, thereby reducing a hypoxaemia-related increase in
ventilatory demand, dynamic hyperinflation and increased exer-
tional breathlessness in some patients (O’Donnell 2001). This
mechanism is supported by the present finding that a higher oxy-
gen dose (> 2 L/min) was associated with a larger decrease in
breathlessness. The finding that the oxygen effect was not stronger
in studies of patients with exertional desaturation might reflect
that the analysis was based on the study mean, and that hetero-
geneity in the level of exertional hypoxaemia among individual
participants might have attenuated the association. Some people
developed hypoxaemia during exercise despite supplemental oxy-
gen therapy that could have increased their breathlessness scores.
The issue is further complicated in that some patients might have
adapted to exertional hypoxaemia, with a reduced ventilatory re-
sponse to hypoxaemia and therefore less benefit of oxygen during
exercise. Another hypothesis is that airflow to the face and upper
airways could relieve breathlessness, possibly through increased af-
ferent feedback mimicking increased ventilatory work (Johnson
2016; Schwartzstein 1987). This could reduce the imbalance be-
tween ventilatory demand and perceived ventilatory work and thus
the level of breathlessness, and may explain why participants did
not prefer to go on, or why no significant change in HRQOL was
evident when oxygen was compared with air delivered through the
same method.
Evidence for use in clinical care
Most evidence of the benefit of oxygen for breathlessness pertains
to symptoms noted during standardised exercise testing in the lab-
oratory setting. The oxygen effect during domiciliary treatment in
daily life was smaller and more uncertain (SMD -0.12, 95% CI -
0.39 to 0.15). More recent double-blinded randomised controlled
trials (RCTs) of oxygen compared with medical air have found no
statistically or clinically relevant effects of domiciliary/ambulatory
oxygen on breathlessness in daily life (Abernethy 2010; Moore
2011). Less efficacy of domiciliary oxygen might reflect insuffi-
cient adherence to therapy or low physical activity due to decon-
ditioning, or the fact that breathlessness in daily life is not assessed
at a comparable time point or after a standardised workload. A
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patient who benefits from oxygen (decreased breathlessness at a
given workload and improved exercise capacity) might increase
his/her activity up to maximal tolerable levels of breathlessness.
We found that the level of breathlessness at peak exercise did not
seem to be affected by oxygen. When breathlessness is recalled in
daily life, reported symptom level might therefore be similar be-
tween people receiving oxygen and those given air, even if oxygen
would in fact be beneficial in some patients. Whether palliative
oxygen in the domiciliary setting is beneficial remains unclear. We
found no evidence to show that oxygen improved HRQOL, but
the data were limited.
Quality of the evidence
We rated the quality of evidence for the effect of oxygen com-
pared with air on breathlessness as low overall upon complet-
ing a GRADE assessment (Summary of findings for the main
comparison). Most evidence pertained to breathlessness measured
during a standardised exercise test (moderate-quality evidence),
whereas evidence was limited for breathlessness during daily life
(low-quality evidence). We rated the quality of evidence showing
an effect of oxygen on HRQOL as low (Summary of findings for
the main comparison).
Potential biases in the review process
Limitations of this systematic review and meta-analysis mainly re-
flect the heterogeneity and methodological limitations of the cur-
rently available body of literature. Although we excluded studies of
participants already qualifying for home oxygen therapy accord-
ing to current guidelines, the review population still included a
wide range of baseline oxygen saturation/partial pressure of oxy-
gen (PaO2). This variability could affect our results if a relation-
ship is found between oxygen saturation and effects of oxygen on
breathlessness. We addressed this issue by performing a subgroup
analysis based on baseline PaO2 (≥ 9.3 kPa) and obtained con-
sistent findings. Additionally, baseline breathlessness and physical
capacity were often insufficiently reported. The review population
likely included participants with varied perceptions of breathless-
ness and physical capacity.
We explored potential bias due to methodological limitations by
excluding studies with high risk for any bias category; this yielded
consistent findings. A possible limitation of this review is that
many studies did not report data on participants dropping out or
withdrawing from the study. Reporting of data only for partic-
ipants who completed the trial might have introduced selection
bias.
Palliative oxygen is prescribed most commonly for seriously ill pa-
tients nearing the end of life; however, these patients are not likely
to participate in randomised trials, especially studies involving an
exercise test. The applicability of review findings to all individuals
with chronic obstructive pulmonary disease (COPD) who require
palliative oxygen is unclear.
Effects of oxygen on breathlessness were driven in part by five
outlier findings among studies with small sample sizes/low levels
of precision. This asymmetry in the funnel plot might indicate the
presence of publication bias. When we excluded the outliers, the
oxygen effect became somewhat smaller (SMD -0.24, 95% CI -
0.34 to -0.15).
Although the funnel plot indicated potential publication bias, we
did not downgrade the quality of the evidence, as a sensitivity
analysis excluding outlying studies yielded similar findings.
Agreements and disagreements with other
studies or reviews
Compared with the 2011 version of this review (Uronis 2011;
Uronis 2015), we have included an additional 14 studies (493
participants) in this update. The finding of the main analysis of
breathlessness is consistent with the previous estimate but is more
precise because we included more studies. Subgroup analyses by
short burst and by oxygen dose were also in agreement with those
of the previous review. Novel subgroup analyses in the present re-
view show that evidence of effects of oxygen pertains mostly to
breathlessness during exercise tests performed in the laboratory
standardised rehabilitation training setting. Evidence is less consis-
tent and of low quality for effects of supplemental oxygen during
daily life. The novel analysis of HRQOL showed no clear effect of
supplemental oxygen compared with air on quality of life.
Ameer 2014 performed a Cochrane meta-analysis (four studies;
331 participants) of the effects of ambulatory oxygen therapy given
for two weeks or longer on breathlessness and HRQOL in the
home setting. When compared with air or no therapy, ambulatory
oxygen therapy was associated with a small reduction in breath-
lessness as measured on the Borg scale (mean difference 0.28, 95%
CI, 0.10 to 0.45). This finding is consistent with our finding
in the non-laboratory setting. The analysis of breathlessness per-
formed by Ameer 2014 included only three studies (McDonald
1995; Eaton 2002; Nonoyama 2007), which we also included in
the present review. Effects on HRQOL as noted in Ameer 2014
were inconsistent, with mean improvements in breathlessness and
fatigue domains but were not related to emotional function or
mastery. Small or inconsistent effects of supplemental oxygen on
HRQOL and lack of clear effect on exercise capacity in Ameer
2014 support the present conclusion that the evidence base for
supplemental oxygen therapy during daily life is limited.
Findings of this review are consistent with recent British Thoracic
Society (BTS) guidelines stating that although ambulatory oxygen
therapy should be offered to patients for use during exercise in a
pulmonary rehabilitation programme, it “should not be routinely
offered to patients who are not eligible for LTOT” (Hardinge
2015).
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Implications for practice
Oxygen given continuously during exercise or activity can relieve
breathlessness in patients with COPD who have no or mild hy-
poxaemia and would not qualify for long-term oxygen therapy.
Evidence was of moderate quality for breathlessness during exer-
cise testing in the laboratory setting and of low quality for effects
on breathlessness during daily life. It is not clear whether the re-
duction in breathlessness shown in the laboratory setting trans-
lates into a clinically important benefit, and no evidence supports
a clinically important benefit from oxygen for breathlessness in
daily life. Short-burst oxygen therapy given before exercise had no
effect and should not be used.
Clinical recommendations
Based on the present findings, supplemental oxygen therapy is
not a first-line treatment for patients with breathlessness. Man-
agement of underlying disease(s) should be optimised. Evidence-
based symptomatic treatment should include individualised reha-
bilitation training (McCarthy 2015), the fan and low-dose opioids
(Ekstrom 2015a; Ekstrom 2015b; Hardinge 2015). In patients
with intractable breathlessness despite these interventions, a trial
of supplemental oxygen could be considered. Guidelines recom-
mend that palliative oxygen should be evaluated only in patients
with hypoxaemia (saturation < 92%) at rest (Hardinge 2015). We
found that the oxygen effect was similar in studies with mean
PaO2 ≥ 9.3 kPa compared with PaO2 < 9.3 kPa, and that a trial
of supplemental oxygen might be reasonable in patients without
resting hypoxaemia, especially in the presence of hypoxaemia dur-
ing limited exertion. Evaluation of the potential benefit of ambu-
latory oxygen should involve the patient’s levels of physical capac-
ity and activity, along with the benefits of oxygen for breathless-
ness and physical capacity in a standardised test such as the six-
minute walking test (6MWT) when compared with air (Hardinge
2015). Patients who perceive decreased breathlessness when re-
ceiving oxygen most often experience this effect within two to
three days of the start of treatment (Abernethy 2010). Therefore,
palliative oxygen therapy should be evaluated after a few days and
withdrawn if patients do not perceive benefit.
Patient quality of life (QOL) factors such as convenience and ad-
verse consequences should be considered in the decision whether
to prescribe oxygen as treatment for patients with breathlessness
who may already be burdened by their illness and other life changes
prominent in the advanced illness setting.
Finally, in considering these results, one must be sure to remember
the downsides of administering oxygen. Oxygen is costly, and, with
current stresses on healthcare systems in many countries, this needs
to be taken into account. Evidence of the effect of supplemental
oxygen on HRQOL is lacking.
In conclusion, we are moderately confident that oxygen can relieve
breathlessness when given during exercise to mildly hypoxaemic
and non-hypoxaemic people with COPD who would not other-
wise qualify for home oxygen therapy. Most evidence pertains to
acute effects during exercise testing; evidence of long-term effects
of oxygen during daily life is less consistent. Findings show that
oxygen did not affect HRQOL.
Implications for research
Current findings on the effect of oxygen therapy versus air have
several important implications for research. First, oxygen affected
breathlessness measured only at iso-time, not at peak exercise. This
confirms the importance of measuring breathlessness at iso-time
with comparable workloads in mechanistic studies and interven-
tional trials.
Although this review confirms that oxygen can decrease exertional
breathlessness in the laboratory setting, studies should focus on
effects of domiciliary and ambulatory oxygen in clinical and daily
life settings. Studies on effects of oxygen on HRQOL and on
different aspects (dimensions) of breathlessness (Laviolette 2014)
are needed, and investigators should identify optimal doses and
routes of oxygen administration, while determining which pa-
tients are most likely to receive beneficial symptomatic effects of
oxygen. Studies of symptomatic benefit should also account for
changes in physical capacity and activity to explore whether oxy-
gen given during daily living could allow increased exercise activity,
although it might not affect reported breathlessness scores. Tools
for measuring physical activity in COPD were recently validated
(Gimeno-Santos 2015).
We found that adverse events were insufficiently assessed and/
or reported. The first population-based longitudinal study of the
risk of burn injury during LTOT was published only recently
(Tanash 2015). Studies quantifying adverse events, patient burden
and potential risks associated with supplemental oxygen therapy
are needed to determine the net clinical benefit of palliative oxygen.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abernethy 2010
Methods Randomised, controlled, triple-blinded (participants, practitioners, investigators), par-
allel-group trial
Participants Inclusion criteria: patients with COPD older than 18 years; PaO2 > 7.3 kPa; refractory
breathlessness related to life-limiting illness (as determined by referring physicians);
maximum treatment for underlying disease; breathlessness at rest or with negligible
exertion ≥ 3 on the MRC categorical breathlessness scale; on stable medications during
the previous week; expected survival ≥ 1 month (as judged by the responsible physician)
)
Exclusion criteria: met criteria for long-term oxygen therapy; history of hypercarbic
respiratory failure related to oxygen; anaemia (haemoglobin < 100 g/L); hypercapnia
(PaCO2 > 6.7 kPa); cognitive impairment (Folstein mini-mental status score < 24/30);
smoking; respiratory or cardiac event in the previous week
Setting: outpatient pulmonary, palliative care, oncology and primary care clinics at 5
sites in Australia, 2 in the USA and 2 in the UK
Method of recruitment of participants: patients referred to the clinics
239 participants randomised (211 completed)
152 participants with COPD
Male 103 (68%)
Mean age: 73.2 (SD 9.9)
Lung function: no data available
Mean baseline SaO2 (%): no data available
Mean baseline PaO2 (kPa): 10.0 (SD 1.5)
Mean PaCO2 (kPa): 5.2 (SD 0.6)
Mean breathlessness morning and evening NRS scores at baseline: 4.7 (SD 2.0) overall;
4.6 (SD 2.0) in the oxygen group; 4.8 (SD 2.0) in the air group
Interventions Domiciliary oxygen (2 L/min) versus room air (2 L/min) delivered continuously from
concentrator by nasal cannula; prescribed for at least 15 hours per day. Duration 7 days
Outcomes Breathlessness measured by NRS (0-10, 0 “none” to 10 “maximal”), defined as breath-
lessness “right now” during morning and evening. Mean of morning and evening scores
used in the meta-analysis
Overall well-being on NRS (0-10) scores in the evening day 7
Treatment preference - categorical at day 7




Bias Authors’ judgement Support for judgement
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Abernethy 2010 (Continued)
Random sequence generation (selection
bias)
Low risk “Randomised to treatment by a central
computer-generated system available (via
web or telephone) through the pharmacy
service at Repatriation General Hospital
(Adelaide, Australia) with balanced blocks
of four patients per stratum, on the basis of
Fisher and Yates’ statistical tables.”
Allocation concealment (selection bias) Low risk “Patients, individuals delivering the inter-
ventions, investigators, and nurses were
masked to treatment assignments. Oxygen
and room air concentrators were identical
in appearance. By use of a standard proto-
col, the medical gas company serving each
site modified half the concentrators to dis-
pense room air without setting off the in-
ternal alarm that sounds when oxygen con-
centrations are low.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk As above
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As above
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 7% attrition for oxygen (overall) and 17%
for air (overall)
Selective reporting (reporting bias) Low risk According to the aims, adequately reported
variables
Other bias Low risk We judged that this trial appeared to be free
of other sources of bias
Bruni 2012a
Methods Randomised, controlled, double-blinded (participants and investigators), cross-over trial
Participants Inclusion criteria: no formal criteria reported. Male patients with severe airway obstruc-
tion and hyperinflation participated in the study. COPD was diagnosed on the basis
of history, physical examination, chest radiograph and results of pulmonary function
studies. All patients had a long history of smoking and were clinically stable and taking
appropriate medication
Exclusion criteria: not stated
Setting: laboratory (Italy)
Method of recruitment of participants: not described
10 participants with COPD classified as “hyperinflators” who exhibited a 0.47 (SD 0.
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Bruni 2012a (Continued)
35 L) increase in chest wall volume
All male
Mean age: 68.1 (SD 6.6)
Mean FEV1 (L): 0.91 (SD 0.3)
Mean FEV1 (% predicted): 32.7 (SD 8.7)
FEV1/FVC: 0.29 (SD 0.1)
Mean baseline SaO2 (%): no data available
Mean baseline PaO2 (kPa): 9.5 (SD 1.2)
Mean PaCO2 (kPa): 5.6 (SD 0.6)
Mean breathlessness at baseline: no data available
Interventions Oxygen (FiO2 0.5) vs room air during 1 symptom-limited cycle test at 75% of peak
work rate
Participants wore a nose-clip and breathed through a low-dead-space mouthpiece; Dou-
glas bag
Outcomes Breathlessness measured by modified Borg at iso-time (mBorg 0-10, 0 “none” to 10
“maximal”)
HRQOL - no data available
Treatment preference - no data available
Adverse effects - no data available
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “In randomised order”; other information
not available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Subjects were blinded to the oxygen con-
centration being breathed as was the inves-
tigator evaluating subjective responses and
performing data analysis.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No data on whether saturation was mea-
sured; but self-rated
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study.
Selective reporting (reporting bias) Low risk Important outcomes were reported.
Other bias Unclear risk Unclear how participants were selected and
whether participants withdrew; data re-
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Bruni 2012a (Continued)
ported only for participants completing the
study
Bruni 2012b
Methods Randomised, controlled, double-blinded (participants, investigators), cross-over trial
Participants Inclusion criteria: no formal criteria reported. Male patients with severe airway obstruc-
tion and hyperinflation participated in the study. COPD was diagnosed on the basis
of history, physical examination, chest radiograph and results of pulmonary function
studies. All patients had a long history of smoking and were clinically stable and taking
appropriate medication
Exclusion criteria: not stated
Setting: laboratory (Italy)
Method of recruitment of participants: not described
6 participants with COPD classified as “non-hyperinflators” because of constant chest
wall volume
Mean age: 68.1 (SD 6.6)
Mean FEV1 (L): 0.91 (SD 0.3)
Mean FEV1 (% predicted): 32.7 (SD 8.7)
FEV1/FVC: 0.29 (SD 0.1)
Mean baseline SaO2 (%): no data available
Mean baseline PaO2 (kPa): 10.3 (SD 0.9)
Mean PaCO2 (kPa): 5.2 (SD 0.1)
Mean breathlessness at baseline: no data available
Interventions Oxygen (FiO2 0.5) vs room air during 1 symptom-limited cycle test at 75% of peak
work rate
Participants wore a nose-clip and breathed through a low-dead-space mouthpiece; Dou-
glas bag
Outcomes Breathlessness measured by modified Borg at iso-time (mBorg 0-10, 0 “none” to 10
“maximal”)
HRQOL - no data available
Treatment preference - no data available
Adverse effects - no data available
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “In randomised order”; other information
not available
Allocation concealment (selection bias) Unclear risk Information not available
34Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bruni 2012b (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Subjects were blinded to the oxygen con-
centration being breathed as was the inves-
tigator evaluating subjective responses and
performing data analysis.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No data on whether saturation was mea-
sured; but self-rated
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study.
Selective reporting (reporting bias) Low risk Important outcomes were reported.
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
Davidson 1988
Methods Randomised, double-blinded (participants and investigators), cross-over trial
Participants Inclusion criteria: exercise tolerance limited by breathlessness secondary to severe
chronic airflow obstruction
Exclusion criteria: angina; impaired cardiac function or locomotor disability that might
contribute to exercise limitation
Setting: laboratory
17 participants (14 completed)
Gender not specified
Mean age: 64.4 (SEM 2.1)
Mean FEV1 (L): 0.79 (SEM 0.0)
Mean FVC (L): 2.1 (SEM 0.11)
Mean baseline SaO2 (%): no data available
Mean baseline PaO2 (kPa): 8.6 (SEM 0.3)
Mean PaCO2 (kPa): 6.0 (SEM 0.4)
Mean breathlessness at baseline: no data available
Interventions Compressed air (4 L/min) vs oxygen (2, 4 or 6 L/min) during 6MWT, cycle ergometer
test or endurance shuttle walk test
Outcomes Breathlessness measured by VAS at the end of exercise (10 cm VAS, “not at all breathless”
to “extremely breathless”)
HRQOL - no data available
Treatment preference - no data available
Adverse effects - no data available
Notes
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Davidson 1988 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised: “The order of
testing in both the oxygen dosing study and
the walking tests was allocated randomly”;
other information not available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind (walking test)
and single-blind (cycle test); other informa-
tion not available
“For walking exercise the tests were per-
formed double blind. For cycling en-
durance it was necessary for the investiga-
tor to determine the bias flow composition
and this part of the study was therefore sin-
gle (patient) blind. To ensure that this did
not affect performance, care was taken to
provide a similar degree of encouragement
as detailed above.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk As above
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data reported only for participants com-
pleting the study. “Not all patients com-
pleted six minutes of exercise when breath-
ing air or the low concentration of oxygen.
”
Reported VAS scores only for 4 L/min for
14 participants after 6 minutes of exercise
Selective reporting (reporting bias) Unclear risk As above
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
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Dean 1992
Methods Randomised, double-blinded (participants and investigators), cross-over trial
Participants Inclusion criteria: age > 50; DLCO < 80% predicted; extensive smoking history; resting
PaO2 > 55 mmHg
Exclusion criteria: active coronary artery disease; congestive heart failure; vascular, or-




Age > 50, but specifics not reported
Mean FEV1 (L): 0.89 (SEM 0.1)
Mean FVC (L): 2.4 (SEM 0.2)
Mean DLCO (mL/min/mmHg): 9.8 (SEM 1.5)
Mean baseline SaO2 (%): no data available
Mean baseline PaO2 (kPa): 9.5 (SE 0.3)
Mean baseline PaCO2 (kPa): no data available
Mean breathlessness at baseline: no data available
Interventions Compressed air vs 40% oxygen during incremental and endurance exercise shuttle walk
tests
Outcomes Breathlessness measured by modified Borg at iso-time (mBorg)
HRQOL - no data available
Treatment preference - no data available
Adverse effects - no data available
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; other informa-
tion not available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind (participants,
study personnel)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Oximetry values were not available to the
patient or supervising physician during en-
durance testing to preserve blinding.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study.
Selective reporting (reporting bias) Low risk Important outcomes were reported.
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Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
Dyer 2012
Methods Randomised, controlled, single-blinded (investigators), parallel-group trial
Participants Inclusion criteria: COPD; desaturated by > 4% to < 90% on exertion at baseline;
improved ≥ 10 % in ESWT with ambulatory O2 (mean 280 m)
Exclusion criteria: any existing home oxygen
Setting: laboratory (Surrey, UK)
Method of recruitment of participants: consecutive patients with COPD referred to 3
PR services in Surrey, UK
55 participants with COPD (47 completed)
Male 30 (64% of 47 completing)
Mean age: air 70 (SD 7); oxygen 68 (SD 8)
Mean FEV1 (L): 1.12 (SD 0.5); oxygen 0.96 (SD 0.4)
Mean FEV1 (% predicted): room air 44 (SD 11); oxygen 39 (SD 16)
Mean baseline SaO2 (%): 94 (SD 2)
Mean baseline PaO2 (kPa): no data available
Mean baseline PaCO2 (kPa): no data available
Mean breathlessness at baseline: CRQ dyspnoea score 3 (SD 1); MRC 3 (SD 1)
Interventions Ambulatory oxygen (2-6 L/min) vs room air during PR and during exertion at home;
delivered via nasal prongs; most participants had cylinders and a few were supplied with
liquid oxygen. Duration of treatment: 6-7 weeks of training, as well as at home during
all activities that induced breathlessness but not at rest
Outcomes Breathlessness measured by CRQ dyspnoea subdomain on a 7-point Likert scale (higher
= good)
HRQOL - CRQ subdomains
Treatment preference - no data available
Adverse effects - number of dropouts
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk By random number tables and sealed en-
velopes
Allocation concealment (selection bias) High risk Measured SaO2 during PR; participants
were unblinded; limited blinding for staff.
“It was not possible to blind participants to
group allocation as sham O2 was not avail-
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able [...] due to limited study resources.”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Single-blinded (staff )
“Exercise tolerance at the end of PR for
all participants was reassessed by [author],
with blinding maintained by all partici-
pants wearing nasal cannulae with an oxy-
gen cylinder attached, carried in a backpack
by an assistant, which was switched off for
the RA group. At the end of PR, exercise
tolerance was reassessed by [author] (blind
to group allocation).”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk As above
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data reported only for participants com-
pleting the study. The number of dropouts
was equal in both groups
Selective reporting (reporting bias) Unclear risk No protocol. Did not report breathlessness
during exercise test after PR
Other bias High risk Per-protocol analysis only
Eaton 2002
Methods Randomised, controlled, double-blind (participants, investigators), cross-over trial
Participants Inclusion criteria: COPD as defined by ATS criteria, exertional breathlessness impacting
daily activities, not fulfilling criteria for LTOT, exertional desaturation (O2 saturation
≤ 88%), ex-smoker, clinically stable for 2 months with standard optimal medical care,
completion of a formal 6-week pulmonary rehabilitation programme
Exclusion criteria: “important co-morbidities (e.g. limiting angina or significant mus-
culoskeletal disability)”
Setting: non-laboratory
50 participants (41 completed)
70% male
Mean age: 57.1 (SD 9.3)
Mean FEV1 (% predicted): 25.9 (SD 8)
Mean baseline SaO2 (%): 94 (SD 1.9)
Mean baseline PaO2 (kPa): 9.2 (SD 1.0)
Mean baseline PaCO2 (kPa): 5.8 (SD 0.7)
Mean breathlessness at baseline: 0.7 (SD 1.0)
Interventions Compressed air (4 L/min) vs oxygen (4 L/min) during both 6MWT and 6-week period at
home during which participants were instructed “to use flow rate of 4 L/min intranasally
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for any activity during which they would normally experience breathlessness”
Outcomes Breathlessness measured by modified Borg (mBorg 0-10, 0 “none” to 10 “maximal”)
HRQOL - CRQ total score, CRQ subdomains, SF-36
Treatment preference - no data available
Adverse effects - number of dropouts
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; other informa-
tion not available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Patients were randomly assigned in a dou-
ble blinded manner to cylinder air or
O2. All cylinders were painted pink, pre-
filled with either air or O2 and identifiable
only by a unique cylinder number, ensur-
ing blinding of both participants and ob-
servers.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As above
Incomplete outcome data (attrition bias)
All outcomes
Low risk “A mixed model approach to crossover tri-
als was employed, which used information
from all patients, including those who did
not complete both time periods.”
Selective reporting (reporting bias) Low risk Important outcomes were reported
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
Eaton 2006
Methods Randomised, controlled, double-blind (participants, investigators), parallel-group trial
Participants Inclusion criteria: 78 hospital inpatients with an acute exacerbation of COPD; moderate
or severe COPD as defined by British Thoracic Society criteria; exertional dyspnoea
interfering with daily activity; resting PaO2 > 60 mmHg at discharge; ability to complete
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HRQOL questionnaires
Exclusion criteria: current smoker; severe comorbidity likely to cause death within
the 6-month study period; resident of a long-term facility in which SBOT is available;
hypercapnia (PaCO2 > 45 mmHg)
Setting: non-laboratory
51 participants (34 completed); 25 in oxygen group; 26 in air group
56% male in oxygen group; 50% male in air group
Mean age: oxygen 77.4 (SD 7.2); air 77.6 (SD 5.7)
Mean FEV1 (L): oxygen 0.9 (SD 0.5); air 0.9 (SD 0.4)
Mean FEV1 (% predicted): oxygen 44 (SD 22); air 39 (SD 17)
Mean baseline SaO2 (%): oxygen 95 (SD 1.9); air 95 (SD 1.6)
Mean baseline PaO2 (kPa): oxygen 9.6 (SD 1.3); air 10.1 (SD 1.7)
Mean baseline PaCO2 (kPa): oxygen 5.3 (SD 0.6); air 5.4 (SD 0.4)
Mean breathlessness at baseline, CRD dyspnoea: oxygen 17.8 (SD 5.0); air 17.5 (SD 4.
2)
Interventions Cylinder oxygen (2 L/min) vs cylinder air (2 L/min) vs usual care during 6-month
domiciliary period. Participants were given standardised instructions “to use they cylinder
gas at 2 L/min via nasal prongs, as necessary for distressing or limiting breathlessness.”
No short-term assessments were performed
Outcomes Breathlessness measured by CRQ dyspnoea score
HRQOL - CRQ total score, CRQ subdomains, SF-36
Treatment preference - no data available
Adverse effects - number of dropouts
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomised using com-
puter-generated randomisation numbers.”
Allocation concealment (selection bias) Low risk “Allocation of cylinders was by a separate
member of the research team not involved
in patient assessment.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “To ensure double-blinding, cylinders, pre-
filled with air or oxygen, were identifi-
able only by a unique cylinder number.
Cylinders were painted pink to ensure they
would not be used in routine clinical care.
”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As above
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data reported only for participants com-
pleting the study.
17 dropouts in total; number of dropouts
was equal in both groups
Selective reporting (reporting bias) Low risk Important outcomes were reported.
Other bias Low risk We judged that this trial appeared to be free
of other sources of bias
Emtner 2003a
Methods Randomised, controlled, double-blind (participants, investigators), parallel-group trial
Participants Inclusion criteria: COPD that is clinically stable with no recent exacerbations; FEV1
< 50% predicted; FEV1/VC < 0.65; resting PaO2 > 55 mmHg; SpO2 > 88% during
constant work rate test while breathing room air
Exclusion criteria: symptomatic cardiovascular comorbidity or other disease that might
contribute to exercise limitation; regular participation in a formal exercise programme
or participation in a formal rehabilitation programme within the past 2 years
Setting: laboratory
30 participants overall (29 completed)
15 participants categorised as “air trained group”
10 male and 5 female
Mean age: 67 (SD 10)
Mean FEV1 (L): 1.01 (SD 0.27)
Mean FVC (L): 2.58 (SD 0.7)
Mean TLC (L): 7.3 (SD 1.2)
Mean RV (L): 4.6 (SD 1.3)
Mean DLCO (mL/min/mmHg): 11.4 (SD 4.4)
Mean baseline SaO2 (%): no data available
Mean baseline PaO2 (kPa): 9.8 (SD 1.0)
Mean baseline PaCO2 (kPa): 5.5 (SD 0.5)
Mean breathlessness at baseline: no data available
Interventions Supplemental oxygen (FiO2 0.30) vs compressed air during constant work rate exercise
During training sessions, gas was delivered at 3 L/min via nasal cannula, connected to
the appropriate tank (compressed air or oxygen) by an unblinded investigator
Incremental and constant work rate tests were performed by inhaling compressed air or
30% oxygen (4 tests). Participants were blinded to the inhaled mixture and breathed
through mouthpiece and low-resistance valve with a nose-clip in place
Outcomes Breathlessness measured by modified Borg (mBorg 0-10, 0 “none” to 10 “maximal”)
HRQOL - CRQ total score, CRQ subdomains, SF-36
Treatment preference - no data available
Adverse effects - number of dropouts
Notes
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization sequence was gener-
ated using numbered sealed envelopes.”
Allocation concealment (selection bias) Low risk Sealed envelopes were used to conceal gen-
erated randomisation sequence from study
investigators
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The nasal cannula tubing was connected
to the appropriate tank (compressed air or
oxygen) by an unblinded investigator. Pa-
tient and staff did not know which gas mix-
ture the patient received (...). Exercise in-
tensity was subsequently adjusted, consid-
ering the subject’s breathlessness and fa-
tigue sensations, by blinded therapists.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “An unblinded investigator measured oxy-
gen saturation periodically; the findings
were never reported to the patients or ther-
apists.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No participants withdrew from this arm of
treatment.
Selective reporting (reporting bias) Low risk According to the aims, adequately reported
variables
Other bias Low risk We judged that this trial appeared to be free
of other sources of bias
Emtner 2003b
Methods Randomised, controlled, double-blind (participants, investigators), parallel-group trial
Participants Inclusion criteria: COPD that is clinically stable with no recent exacerbations; FEV1
< 50% predicted; FEV1/VC < 0.65; resting PaO2 > 55 mmHg; SpO2 ≥ 88% during
constant work rate test while breathing room air
Exclusion criteria: symptomatic cardiovascular comorbidity or other disease that might
contribute to exercise limitation; regular participation in a formal exercise programme
or participation in a formal rehabilitation programme within the past 2 years
Setting: laboratory
30 participants overall (29 completed)
14 participants categorised as “oxygen-trained group”
8 male and 6 female
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Mean age: 66 (SD 7)
Mean FEV1 (L): 1.01 (SD 0.33)
Mean FVC (L): 2.7 (SD 0.8)
Mean TLC (L): 7.2 (SD 1.6)
Mean RV (L): 4.1 (SD 0.9)
Mean DLCO (mL/min/mmHg): 10.9 (SD 3.5)
Mean baseline SaO2 (%): no data available
Mean baseline PaO2 (kPa): 9.5 (SD 1.1)
Mean baseline PaCO2 (kPa): 5.4 (SD 0.7)
Mean breathlessness at baseline: no data available
Interventions Supplemental oxygen (FiO2 0.30) vs compressed air during constant work rate exercise
During training sessions, gas was delivered at 3 L/min via nasal cannula, connected to
the appropriate tank (compressed air or oxygen) by an unblinded investigator
Incremental and constant work rate tests were performed by inhaling compressed air or
30% oxygen (4 tests). Participants were blinded to the inhaled mixture and breathed
through mouthpiece and low-resistance valve with a nose-clip in place
Outcomes Breathlessness measured by modified Borg (mBorg 0-10, 0 “none” to 10 “maximal”)
HRQOL - CRQ total score, CRQ subdomains, SF-36
Treatment preference - no data available
Adverse effects - number of dropouts
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization sequence was gener-
ated using numbered sealed envelopes.”
Allocation concealment (selection bias) Low risk Sealed envelopes were used to conceal gen-
erated randomisation sequence from study
investigators
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The nasal cannula tubing was connected
to the appropriate tank (compressed air or
oxygen) by an unblinded investigator. Pa-
tient and staff did not know which gas mix-
ture the patient received (...). Exercise in-
tensity was subsequently adjusted, consid-
ering the subject’s breathlessness and fa-
tigue sensations, by blinded therapists.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “An unblinded investigator measured oxy-
gen saturation periodically; the findings
were never reported to the patients or ther-
apists.”
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Incomplete outcome data (attrition bias)
All outcomes
Low risk “One patient from the oxygen-trained
group was excluded because of illness dur-
ing the postintervention testing period.”
Selective reporting (reporting bias) Low risk According to the aims, adequately reported
variables
Other bias Low risk We judged that this trial appeared to be free
of other sources of bias
Eves 2006
Methods Randomised, controlled, double-blinded (participants, investigators), cross-over trial
Participants Inclusion criteria: clinically stable moderate to severe COPD





Mean age: 65 (SD 11)
Mean FEV1 (L): 1.66 (0.59)
Mean FVC (L): 3.81 (0.99)
Mean baseline SaO2 (%): no data available
Mean baseline PaO2 (kPa): 9.1 (SD 0.9)
Mean baseline PaCO2 (kPa): 4.9 (SD 0.4)
Mean breathlessness at baseline: no data available
Interventions Medical air vs 40% oxygen vs heliox vs heliox/oxygen during constant-load cycling.
Throughout exercise, humidified gases were passed into a reservoir bag and supplied
through a low-resistance 2-way breathing valve
Outcomes Breathlessness measured by modified Borg (mBorg 0-10, 0 “none” to 10 “maximal”)
HRQOL - no data available
Treatment preference - no data available
Adverse effects - no data available
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “During the other two visits, four constant-
load symptom-limited exercise trials were
performed in a random order”; other infor-
mation not available
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Allocation concealment (selection bias) Unclear risk Information on concealment of allocation
not available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Throughout exercise, humidified gases
were passed into a reservoir bag and sup-
plied through a low-resistance two-way
breathing valve. The patients were blinded
to the gas mixture used and were asked not
to talk during, or for a short period after, ex-
ercise due to the change in vocal tone with
helium.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Two research assistants, blinded to the gas
mixture used, consistently encouraged pa-
tients to exercise for as long as possible.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study.
Selective reporting (reporting bias) Low risk According to the aims, adequately reported
variables
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
Haidl 2004
Methods Randomised, controlled, unblinded, parallel-group trial
Participants Inclusion criteria: COPD diagnosis (per “current clinical guidelines”); FEV1/FVC < 0.
70; PCO2 > 45 mmHg at rest on 2 different days or increase in PCO2 after cycle testing
> 45 mmHg; PO2 at rest > 55 mmHg; mean nocturnal oxygen saturation > 90%
Exclusion criteria: malignant disease; left heart failure or other significant comorbidities
(e.g. severe renal failure, severe diabetes)
Setting: non-laboratory
28 participants (15 dropouts during 3-year follow-up)
26 (93%) male
Mean age: oxygen group 65.7 (SD 6.7); controls 64.5 (SD 6.4)
Mean FEV1 (% predicted): oxygen group 38.8 (8.4); controls 42.7 (11.8)
Mean baseline SaO2 (%): no data
Mean baseline PaO2 (kPa): oxygen group 9.0 (SD 0.9); controls 8.7 (SD 0.8)
Mean baseline PaCO2 (kPa): oxygen group 5.3 (SD 0.4); controls 5.6 (SD 0.5)
Mean breathlessness at baseline: oxygen group 5.0 (SD 2.1); controls 5.0 (SD 1.5)
Interventions LTOT (2 L/min ≥ 15 hours/d) vs control (no treatment) delivered through nasal cannula
connected to gas concentrators
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Outcomes Breathlessness measured by modified Borg (mBorg 0-10, 0 “none” to 10 “maximal”)
HRQOL - no data available
Treatment preference - no data available
Adverse effects - number of dropouts
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Information not available
Allocation concealment (selection bias) Low risk Participants’ randomisation status was un-
known to staff performing their tests
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded. Control group received usual
care (no sham oxygen)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk See above.
Incomplete outcome data (attrition bias)
All outcomes
High risk Data reported only for participants com-
pleting the study. Both treatment groups
were complete at 1 year, when assessment
was undertaken. Study planned to measure
differences at 3 years, but attrition rates pre-
vented this (15 dropouts during 3-year fol-
low-up)
Selective reporting (reporting bias) Low risk Important outcomes were reported.
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
Ishimine 1995
Methods Randomised, controlled, double-blinded (participants, investigators), cross-over study
Participants Inclusion criteria: male with “stable” COPD or chronic bronchitis; moderate to severe
obstruction; PaO2 > 60 torr at rest
Exclusion criteria: not available (not specified in Cochrane translation)
Setting: laboratory
22 participants
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All men
Mean age: 69 (SD 7)
Mean FEV1 (L): 1.02 (0.51)
Mean FVC (L): 2.26 (0.57)
Mean baseline SaO2 (%): no data
Mean baseline PaO2 (kPa): 10.1 (SD 1.1)
Mean baseline PaCO2 (kPa): no data
Mean breathlessness at baseline: no data
Interventions Room air vs compressed air (3 L/min) vs oxygen (3 L/min) during 6MWT
Outcomes Breathlessness measured by a questionnaire involving 8 questions; each question was
answered on a 100-mm horizontal line with anchors from the modified Borg
HRQOL - no data available
Treatment preference - no data available
Adverse effects - no data available
Notes Translated from Japanese and assessed with the translation sheet
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; other informa-
tion not available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Placebo controlled; blinding of assessors
could not be ascertained
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding of assessors could not be ascer-
tained.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data reported only for participants com-
pleting the study
Selective reporting (reporting bias) Unclear risk Information not available
Other bias Unclear risk Unclear how participants were selected and
whether they withdrew; blinding unclear
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Methods Randomised, double-blinded (participants, investigators), placebo-controlled, cross-over
trial
Participants Inclusion criteria: participants with COPD (ATS grade II/III) with ≥ 30 days of clinical
stability; participating in respiratory rehab programme; FEV1 < 55% and/or FEV1 ratio
< 50%; resting PaO2 > 60 mmHg
Exclusion criteria: peripheral vascular disease; cardiac failure; active CAD
Setting: laboratory
9 participants, classified as “non-de-saturators”
All male
Mean age: 70 (SEM 3)
Mean FEV1 (L): 0.9 (SEM 0.8)
Mean FVC (% predicted): 63 (SEM 6)
Mean TLC (L): 7.4 (SEM 0.4)
Mean RV (L): 4.4 (SEM 0.39)
Mean baseline SaO2 (%): 96 (SEM 0.5))
Mean baseline PaO2 (kPa): 10.5 (SE 0.4)
Mean baseline PaCO2 (kPa): 5.3 (SE 0.2)
Mean breathlessness at baseline: 0.56 (SE 0.3)
Interventions Room air vs compressed air (3, 6, 9, 12 L/min) vs oxygen (3, 6, 9, 12 L/min) during
6MWT - amount of oxygen increased on the basis of desaturation during exercise. Two
indistinguishable cylinders located at the middle of the corridor - 1 with compressed air
(CA) and 1 with oxygen - were connected by a Y-piece to a 15-m tube, ending in a nasal
cannula
Outcomes Breathlessness measured by modified Borg (mBorg 0-10, 0 “none” to 10 “maximal”)
HRQOL - no data available
Treatment preference - no data available
Adverse effects - no data available
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; other informa-
tion not available
Allocation concealment (selection bias) High risk “One person, who knew the randomly as-
signed sequence, opened the valve and reg-
ulated the gas flow as requested by an-
other technician, who walked behind the
patient recording the SaO2 measured by
pulse oximetry (SpO2) values. Both this
technician and the patient were blind about
which gas was added.”
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk As above, and “Two indistinguishable
cylinders located at the middle of the corri-
dor, one with compressed air (CA) and one
with oxygen, were connected by a Y-piece
to a 15-m tube ending in a nasal cannula.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study.
Selective reporting (reporting bias) Low risk According to the aims, adequately reported
variables
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
Jolly 2001b
Methods Randomised, double-blinded (participants, investigators), cross-over trial
Participants Inclusion criteria: patients with COPD (ATS grade II/III) with ≥ 30 days of clinical
stability; participating in respiratory rehab programme; FEV1 < 55% and/or FEV1 ratio
< 50%, resting PaO2 > 60 mmHg
Exclusion criteria: peripheral vascular disease; cardiac failure; active CAD
Setting: laboratory
11 participants classified as “desaturators,” defined by a fall in SpO2 ≥ 5% to < 90%
during the 6MWT on air
10 male and 1 female
Mean age: 67 (SEM 2)
Mean FEV1 (L): 0.9 (SEM 0.8)
Mean FVC (% predicted): 68 (SEM 8)
Mean TLC (L): 7.1 (SEM 0.6)
Mean RV (L): 4.2 (SEM 0.45)
Mean baseline SaO2 (%): 95 (SE 0.3)
Mean baseline PaO2 (kPa): 9.9 (SE 0.3)
Mean baseline PaCO2 (kPa): 5.5 (SE 0.2)
Mean breathlessness at baseline: 0.7 (SD 1.0)
Interventions Room air vs compressed air (3, 6, 9, 12 L/min) vs oxygen (3, 6, 9, 12 L/min) during
6MWT - amount of oxygen increased on the basis of desaturation during exercise. Two
indistinguishable cylinders located at the middle of the corridor - 1 with compressed air
(CA) and 1 with oxygen - were connected by a Y-piece to a 15-m tube, ending in a nasal
cannula
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Outcomes Breathlessness measured by modified Borg (mBorg 0-10, 0 “none” to 10 “maximal”)
HRQOL - no data available
Treatment preference - no data available
Adverse effects - no data available
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; other informa-
tion not available
Allocation concealment (selection bias) High risk “One person, who knew the randomly as-
signed sequence, opened the valve and reg-
ulated the gas flow as requested by an-
other technician, who walked behind the
patient recording the SaO2 measured by
pulse oximetry (SpO2) values. Both this
technician and the patient were blind about
which gas was added.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk As above, and “Two indistinguishable
cylinders located at the middle of the corri-
dor, one with compressed air (CA) and one
with oxygen, were connected by a Y-piece
to a 15-m tube ending in a nasal cannula.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As above
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study.
Selective reporting (reporting bias) Low risk According to the aims, adequately reported
variables
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
51Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Killen 2000
Methods Randomised, single-blind (participants), cross-over trial
Participants Inclusion criteria: COPD predominantly related to smoking; considered for symp-
tomatic oxygen therapy; had stairs at home and found that ascending these produced
breathlessness; desaturation to below 90% on ascent of 22 steps
Exclusion criteria: history of ischaemic heart disease, left ventricular failure or other
cause of reduced mobility such as severe arthritis; already on long-term oxygen or fulfilling
the criteria for long-term oxygen therapy
Setting: non-laboratory
18 participants
8 male and 10 female
Mean age: 67.5 (IQR 60.5 to 74.3)
Median FEV1 (L): 0.53 (IQR 0.45 to 0.76)
Median DLCO (% predicted): 44 (IQR 28 to 64)
Mean baseline SaO2 (%): median 94 (IQR 91 to 95)
Mean baseline PaO2 (kPa): no data available
Mean baseline PaCO2 (kPa): no data available
Mean breathlessness at baseline: no data available
Interventions Oxygen (2 L/min) vs compressed air 5 minutes before and/or 5 minutes after ascending
22 steps. During the 5 minutes before and after these ascents. they breathed from a
cylinder of compressed air or oxygen, delivered at 2 L/min via face mask
Outcomes Breathlessness measured by 100-mm VAS (“not at all breathless” to “extremely breath-
less”)
HRQOL - no data available
Treatment preference - no data available
Adverse effects - no data available
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The order of the ascents was determined
by randomisation within a Latin square.”
Allocation concealment (selection bias) Unclear risk Information on concealment of allocation
not available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “During the five minutes before and after
these ascents they breathed from a cylinder
of either compressed air or oxygen, deliv-
ered at 2 l/min via a face mask, in a single
blind manner.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk As above
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Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed
Selective reporting (reporting bias) Low risk According to the aims, adequately reported
variables
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
Knebel 2000
Methods Randomised, double-blinded (participants, investigators), cross-over trial
Participants Inclusion criteria: adults with obstructive lung disease due to AAT deficiency; FEV1 <
70% of predicted; FEV1/FVC < 0.70
Exclusion criteria: FEV1 < 1 L; hospitalisation in preceding 3 weeks; conditions pro-
hibiting or limiting exercise; current use of oxygen; inability to understand English
Setting: laboratory
33 participants (31 completed)
22 male and 13 female
Mean age: 47 (SD 7)
Mean FEV1 (% predicted): 48 (SD 13)
Mean TLC (% predicted): 105 (SD 14)
Mean baseline SaO2 (%): 97.1% (SD 1.7)
Mean baseline PaO2 (kPa): no data available
Mean baseline PaCO2 (kPa): no data available
Mean breathlessness at baseline: 0.5 (SD 0.9)
Interventions Oxygen (4 L/min) vs compressed air (4 L/min) during 6MWT. Both gases were delivered
by nasal cannula, using the minimum dose shown to improve exercise performance, 4
L/min
Outcomes Breathlessness measured by 10-cm horizontal VAS (0 = “No shortness of breath” and 10
= “Shortness of breath as bad as it can be”)
HRQOL - no data available
Treatment preference - no data available
Adverse effects - number of dropouts
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “A table of random numbers identified the
order of administration.”
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Knebel 2000 (Continued)
Allocation concealment (selection bias) Unclear risk Information not available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The tanks were covered so neither the pa-
tient nor the researcher knew which gas was
being used.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Two patients were unable to complete all
of the walks because of unrelated problems.
” Data on remaining participants were anal-
ysed in the study
Selective reporting (reporting bias) Low risk According to the aims, adequately reported
variables
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
Kurihara 1989
Methods Randomised, single-blind, cross-over trial
Participants Inclusion criteria: “COPD”
Exclusion criteria: none mentioned (Cochrane translation)
Setting: laboratory
14 participants
11 male and 3 female
Mean age: 62 (SD 10.2)
Mean FEV1 (L): 0.67 (SD 0.23)
Mean FVC (% predicted): 58.3 (SD 6.2)
Mean baseline SaO2 (%): no data available
Mean baseline PaO2 (kPa): 9.2 (SD 1.2)
Mean baseline PaCO2 (kPa): no data available
Mean breathlessness at baseline: no data available
Interventions Breathlessness by modified Borg scale and distance walked on treadmill
Outcomes Breathlessness measured by modified Borg (mBorg, 1 “none” to 10 “extremely severe”)
HRQOL - no data available
Treatment preference - no data available
Adverse effects - no data available
Notes Worked from translation sheet from Japanese as opposed to from the entire article
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Kurihara 1989 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; no other infor-
mation available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Single-blind study; no other information
available
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk See above.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Information not available
Selective reporting (reporting bias) Unclear risk Information not available
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
Laude 2006
Methods Randomised, controlled, double-blinded (participants, investigators), cross-over trial
Participants Inclusion criteria: COPD confirmed by FEV1 < 80% predicted, FEV1/FVC < 70%, a
change in FEV1 < 200 mL or < 15% of baseline, 15 minutes after inhaled salbutamol,
dyspnoea on exertion defined by a Borg score after exercise ≥ 3 and freedom from
exacerbations in the 6 weeks preceding the study
Exclusion criteria: required domiciliary oxygen therapy; had resting hypercapnia,
anaemia or a significant cardiac diagnosis
Setting: laboratory
Method of recruitment of participants: outpatients recruited from respiratory clinics at
the 3 hospitals
82 participants (76 participants analysed in air group, 78 participants in oxygen group)
Gender not specified
Mean age: 69.7 (range 46 to 84)
Mean FEV1 (L): 1.1 (SD 0.4)
Mean FVC (L): 2.6 (SD, 0.8)
Mean baseline SaO2 (%): 94 (SD 2.3)
Mean baseline PaO2 (kPa): no data available
Mean baseline PaCO2 (kPa): no data available
Mean breathlessness at baseline: 1.8 (SD 1.1)
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Laude 2006 (Continued)
Interventions Oxygen (0.28) vs medical air during treadmill exercise, delivered through a non-rebreath-
ing mask and demand valve system connected to a portable cylinder
Outcomes Breathlessness measured by modified Borg (mBorg 0-10, 0 “none” to 10 “maximal”)
and 100-mm VAS
HRQOL - no data available
Treatment preference - no data available
Adverse effects - number of dropouts
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Independent randomisation of the gas
mixtures was done using a Latin square de-
sign.”
Allocation concealment (selection bias) Unclear risk Information not available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “In all tests, the investigator carried the
gas cylinder walking beside the patient and
gave no encouragement. Patients were in-
structed not to speak while breathing the
gas mixtures and for 2 min afterwards to
avoid unblinding...would have un-blinded
both patient and investigator.”
“Cylinders were coded as to content to
maintain blinding.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk As above
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Intention-to-treat population reported;
specific details of how missing data were
handled in the analysis not available
Selective reporting (reporting bias) Low risk Important outcomes reported
Other bias Unclear risk Unclear how participants were selected,
data reported only for participants com-
pleting the study (7 withdrawals in total)
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Leach 1992
Methods Randomised, double-blinded (participants, investigators), cross-over trial
Participants Inclusion criteria: severely reduced exercise tolerance secondary to chronic respiratory
disease; no previous experience of exercise testing






Mean FEV1 (L): 0.74 (0.3)
Mean FVC (L): 1.94 (0.5)
Mean baseline SaO2 (%): no data available
Mean baseline PaO2 (kPa): 8.7 (SD 2.3)
Mean baseline PaCO2 (kPa): 5.6 (SD 1.2)
Mean breathlessness at baseline: no data available
Interventions Oxygen (2, 4 or 6 L/min) vs compressed air (4 L/min) delivered through face mask
during 6MWT and endurance shuttle walk test (walk as far as possible and stop when
unable to go farther)
Outcomes Breathlessness measured by 10-cm VAS (“not at all breathless” to “extremely breathless”)
HRQOL - no data available
Treatment preference - no data available
Adverse effects - no data available
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The order of the four tests in which the gas
was carried by the patient was randomised
on each day.”
Allocation concealment (selection bias) Unclear risk Information not available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “The subject and the investigator were
blinded to the flow rate and type of gas sup-
plied, although in practice the investigator
was frequently able to determine those pa-
tients having oxygen from the oxygen sat-
uration shown by ear oximetry.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk See above.
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Leach 1992 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed
Selective reporting (reporting bias) Low risk Adequately reported variables
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
Lewis 2003
Methods Randomised, single-blinded (participants), placebo-controlled, cross-over trial
Participants Inclusion criteria: moderate to severe COPD according to BTS criteria; significant
self-reported breathlessness; on optimal treatment; no exacerbation of disease for > 4
weeks before study, with exacerbation defined as “a deterioration in respiratory symptoms
requiring treatment with corticosteroids or antibiotics or both”
Exclusion criteria: significant limiting or unstable comorbidities
Setting: laboratory
Method of recruitment of participants: Participants were identified through respiratory
outpatient services at Green Lane Hospital, Auckland, New Zealand
22 participants (18 completed)
16 male and 2 female
Mean age: 68.7 (SD 10.1)
Mean FEV1 (L): 0.91 (SD 0.4)
Mean baseline SaO2 (%): 94 (SD 1.6)
Mean baseline PaO2 (kPa): no data available
Mean baseline PaCO2 (kPa): no data available
Mean breathlessness at baseline: 0.4 (SD 0.5)
Interventions Oxygen (2 L/min) vs air (2 L/min) before 6MWT, delivered via nasal cannulae
Outcomes Breathlessness measured by modified Borg at end of exercise (mBorg 0-10, 0 “none” to
10 “maximal”)
HRQOL - no data available
Treatment preference - no data available
Adverse effects - number of dropouts
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; other informa-
tion not available
Allocation concealment (selection bias) Unclear risk Information not available
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Lewis 2003 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “...identical cylinders in a single-blind fash-
ion. Due to the need for monitoring of oxy-
gen saturation by the physiotherapist, dou-
ble-blinding was not possible.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk As above
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data reported only for participants com-
pleting the study (4 withdrawals)
Selective reporting (reporting bias) Low risk Important outcomes were reported.
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
Maltais 2001
Methods Randomised, double-blinded (participants, investigators), cross-over trial
Participants Inclusion criteria: “moderate to severe” COPD with diagnosis based on previous or
current smoking history and PFTs (including spirometry, lung volume and CO diffusing
capacity); “stable disease”
Exclusion criteria: clinical cardiovascular, neurological or any condition that could alter
the capacity to perform an exercise test according to medical history, physical exam,




Mean age: 63 (SEM 3)
Mean FEV1 (L): 1.04 (SEM 0.1)
Mean FVC (L): 2.64 (SEM 0.2)
Mean baseline SaO2 (%): no data available
Mean baseline PaO2 (kPa): 11.3 (SEM 0.5)
Mean baseline PaCO2 (kPa): 4.9 (SEM 0.3)
Mean breathlessness at baseline: no data available
Interventions Room air vs oxygen (FiO2 0.75) delivered through a mouthpiece during exercise testing
Outcomes Breathlessness measured by modified Borg (mBorg 0-10, 0 “none” to 10 “maximal”)
HRQOL - no data available
Treatment preference - no data available
Adverse effects - no data available
Notes
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Maltais 2001 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients performed two exercise tests in
a random order”; other information not
available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Patients and the physician supervising the
exercise tests were blinded as to which in-
spiratory gas was used.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study.
Selective reporting (reporting bias) Low risk Adequately reported variables
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
McDonald 1995
Methods Randomised, double-blinded (participants, investigators), cross-over trial
Participants Inclusion criteria: stable severe COPD; resting PaO2 > 60 mmHg; exertional breath-
lessness sufficient to interfere with daily activities; non-smoker; no exacerbations in pre-
ceding 3 months; maximal bronchodilator and/or corticosteroid therapy
Exclusion criteria: symptomatic cardiac dysfunction; angina pectoris; locomotor dis-
ability
Setting: non-laboratory
33 participants (26 completed)
24 male and 2 female
Mean age: 73 (SD 6)
Mean FEV1 (L): 0.9 (SD 0.4)
Mean DLCO (mL/min/mmHg): 10.6 (SD 2.4)
Mean baseline SaO2 (%): 94 (SD 2.1)
Mean baseline PaO2 (kPa): 9.2 (SD 1.1)
Mean baseline PaCO2 (kPa): 5.5 (SD 0.4)
Mean breathlessness at baseline: no data available
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McDonald 1995 (Continued)
Interventions Oxygen vs compressed air delivered via nasal cannula at 4 L/min over long-term (suc-
cessive 6-week periods during which participants were instructed to use portable gas
cylinder during ”any activity that would normally induce dyspnoea). Participants used
portable gas cylinders fitted with a demand gas delivery system at a flow rate of 4 L/min
intranasally
Outcomes Breathlessness measured by modified Borg at end of exercise (mBorg 0-10, 0 “none” to
10 “maximal”)
HRQOL - CRQ subdomains
Treatment preference - no data available
Adverse effects - number of dropouts
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; other informa-
tion not available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “All gases were delivered from camou-
flaged cylinders, and both the patients and
the investigator performing the tests were
blinded to their contents.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As above
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data reported only for participants com-
pleting the study (7 withdrawals)
Selective reporting (reporting bias) Unclear risk According to the aims, adequately reported
variables
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
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McKeon 1988a
Methods Randomised, double-blind (participant and investigator), cross-over trial
Participants Inclusion criteria: COPD with “significant disability with exertional breathlessness
despite treatment with inhaled and oral bronchodilators”; FEV1/FVC < 0.60 and TLC
> 80% predicted with no significant change after bronchodilator; “stable condition”
Exclusion criteria: not studied during exercise with history of angina, recent myocardial
infarction, exercise-induced syncope or left ventricular failure
Setting: laboratory
Method of recruitment of participants: consecutive patients with COPD referred for
assessment of need for oxygen therapy (Newcastle, Australia)
20 participants
13 male and 7 female
Mean age: 63.2 (SD 10)
Mean FEV1 (L): 0.79 (SD 0.3)
Mean FVC (L): 2.30 (SD 0.7)
Mean TLC (% predicted): 122 (SD 24)
Mean RV (% predicted): 206 (SD 60)
Mean DLCO (% predicted): 55 (SD 32)
Mean baseline SaO2 (%): 90 (SD 3)
Mean baseline PaO2 (kPa): 7.7 (SD 1.2)
Mean baseline PaCO2 (kPa): 5.9 (SD 1.2)
Mean breathlessness at baseline: no data available
Interventions Compressed air vs oxygen via nasal cannula at 2.5 L/min during treadmill test
Outcomes Breathlessness measured by 300-mm VAS
HRQOL - no data available
Treatment preference - no data available
Adverse effects - no data available
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; information not
available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Neither the patient nor the operator knew
whether compressed air or supplemental
oxygen had been given. Patients were told
that both cylinders contained oxygen, but
in different concentrations.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above.
62Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
McKeon 1988a (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study.
Selective reporting (reporting bias) Low risk According to the aims, adequately reported
variables
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
McKeon 1988b
Methods Randomised, controlled, double-blind (participant and investigator), cross-over trial
Participants Inclusion criteria: COPD with “significant disability with exertional breathlessness
despite treatment with inhaled and oral bronchodilators”; “stable condition” at the time
of the study
Exclusion criteria: not stated
Setting: laboratory
21 participants
11 women and 10 men
Mean age: 62 (SD 9)
Mean FEV1 (L): 0.77 (SD 0.4)
Mean FEV1 (% predicted): 29 (SD 13)
Mean FVC (L): 2.00 (SD 0.9)
Mean FVC (% predicted): 58 (SD 20)
Mean RV (L): 3.53 (SD 0.9)
Mean TLC (L): 5.97 (SD 1.3)
Mean baseline PaO2 (kPa): 8.9 (SD 1.5)
Mean breathlessness at baseline: no data available
Interventions Oxygen vs air delivered via nasal cannula at 4 L/min during treadmill test
Outcomes Breathlessness measured by 300-mm VAS
HRQOL - no data available
Treatment preference - no data available
Adverse effects - no data available
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; no other infor-
mation available
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McKeon 1988b (Continued)
Allocation concealment (selection bias) Unclear risk Cylinders prepared by technician not in-
volved in the study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical cylinders used in the study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study.
Selective reporting (reporting bias) Low risk According to the aims, adequately reported
variables
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
Miki 2012
Methods Randomised, controlled, single-blinded (participants), cross-over trial
Participants Inclusion criteria: COPD not stated as criterion, but study included patients with FEV1 /
FVC < 0.7; clinical stability defined as no respiratory infection for ≥ 4 weeks before the
exercise test; ability to tolerate exercise test for ≥ 4 minutes; and exercise limitation due
primarily to exertional breathlessness during CPET (breathing discomfort alone or in
conjunction with leg discomfort was the primary reason for stopping exercise)
Exclusion criteria: significant pathology including neuromuscular, cardiac and/or pe-
ripheral vascular disease, malignancy or anaemia; qualified for LTOT before the exercise
test
Setting: laboratory (Japan)
Method of recruitment of participants: no data
35 participants
All male
Mean age: 70.4 (SD 5.7)
Mean FEV1 (L): 1.13 (SD 0.5)
Mean FEV1 (% predicted): 43.1 (SD 17.4)
FEV1/FVC: 0.46 (SD 13.5)
Mean baseline SaO2 (%): no data available
Mean baseline PaO2 (kPa): oxygen: 12.5 (SD 1.7); air: 10.2 (SD 1.3)
Mean baseline PaCO2 (kPa): oxygen: 5.3 (SD 0.7); air: 5.1 (SD 0.7)
Mean breathlessness at baseline: oxygen: 0.1 (SD 0.2); air: 0.1 (SD 0.4)
Interventions Oxygen (FiO2 0.24) vs compressed air during 2 symptom-limited incremental exercise
tests. Breathed through a mask attached to a low-resistance, 2-way, non-rebreathing valve
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Miki 2012 (Continued)
from gas cylinders through 200-L Douglas bag
Outcomes Breathlessness measured by modified Borg at iso-time (mBorg 0-10, 0 “none” to 10
“maximal”)
HRQOL - no data available
Treatment preference - no data available
Adverse effects - no data available
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; no other infor-
mation available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Single-blinded (participants): “Patients
were blinded as to which oxygen concen-
tration they were breathing.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Information not available
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All participants completed the study.
Selective reporting (reporting bias) Low risk Important outcomes were reported.
Other bias Unclear risk Unclear how participants were selected;
blinding not optimal
Moore 2009
Methods Randomised, controlled, double-blinded (participants and study personnel), cross-over
trial
Participants Inclusion criteria: patients with a clinical diagnosis of COPD attending the respiratory
laboratory for routine breathing tests
Exclusion criteria: use of short-term bronchodilators within 4 hours; receipt of supple-
mental oxygen within 20 minutes
Setting: tertiary hospital, not stated if single-centre, Melbourne, Australia
Method of recruitment of participants: Patients with a clinical diagnosis of COPD
attending the respiratory laboratory for routine breathing tests were invited to participate
in the study
55 participants (51 completed)
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Moore 2009 (Continued)
Male 40
Mean age: 72.6 (SD 9.7)
Mean FEV1 (L): 1.40 (SD 0.78)
Mean FEV1 (% predicted): 54.7 (SD 24.9)
Mean baseline SaO2 (%): 95 (SD 3.2)
Mean baseline PaO2 (kPa): no data available
Mean baseline PaCO2 (kPa): no data available
Mean breathlessness at baseline: no data available
Interventions Oxygen (44%) vs medical air via mouthpiece. Breathing circuit included a 100-L Douglas
bag, a Hans Rudolf wide bore, non-rebreathing valve
Outcomes Breathlessness - modified Borg
HRQOL - no data available
Treatment preference - no data available
Adverse effects - no data available
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; other informa-
tion not available
Allocation concealment (selection bias) Unclear risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded. “The study gases were de-
livered to the Douglas bag from cylinders
of identical
appearance.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As above
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data reported only for participants com-
pleting the study (1 withdrawal)
Selective reporting (reporting bias) Low risk Important outcomes were reported.
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
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Moore 2011
Methods Randomised, controlled, double-blinded (participants and study personnel), parallel-
group trial
Participants Inclusion criteria: clinically stable ex-smokers with COPD on optimal medical treat-
ment; PaO2 > 7.3 kPa at rest breathing room air; and moderate to severe exertional
breathlessness (mMRC Dyspnoea Scale grade > 2)
Exclusion criteria: patients with PaCO2 > 6.0 kPa undergoing repeat arterial blood gas
analysis after breathing oxygen at 6 L/min, at rest, for 30 minutes; excluded if PaCO2
increased by more than 0.7 kPa
Setting: tertiary hospital, not stated if single centre, Melbourne, Australia
Method of recruitment of participants: not described.
143 participants (139 completed)
Male 99 (69%), female 44
Mean age: 71.8 (SD 9.8)
Mean FEV1 (L): 1.16 (SD 0.51)
Mean baseline SaO2 (%): no data available
Mean baseline PaO2 (kPa): oxygen: 9.7 (SD 8.2); air: 9.3 (SD 1.1)
Mean baseline PaCO2 (kPa): oxygen: 5.4 (SD 0.7); air: 5.4 (SD 0.6)
Mean breathlessness at baseline: oxygen: 17.6 (SD 5.2); air: 17.5 (SD 4.9)
Interventions Domicilary oxygen vs air at 6 L/min with 2-week run-in; 12 weeks ambulatory treatment.
Delivered through nasal prongs by gas cylinders
Outcomes Breathlessness measured by CRQ dyspnoea domain
HRQOL - CRQ total score, CRQ subdomains
Treatment preference - no data available
Adverse effects - number of dropouts
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Assigned them randomly to cylinder air or
cylinder oxygen using a computer-gener-
ated sequence and concealed allocation”
Allocation concealment (selection bias) Low risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Study personnel and participants were
blinded to group allocation. Cylinders were
of identical appearance.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As above
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Moore 2011 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data reported only for participants com-
pleting the study. The number of dropouts
was equal in both groups (4 dropouts in
total)
Selective reporting (reporting bias) Low risk According to the aims, adequately reported
variables.
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
Nandi 2003
Methods Randomised, controlled, double-blinded (participants, investigators), cross-over trial
Participants Inclusion criteria: FEV1 < 60% predicted with < 15% reversibility to inhaled salbuta-
mol; smoking history > 20 pack-years; exertional desaturation ≥ 4% on pulse oximetry
during submaximal exertion (corridor walking)
Exclusion criteria: any other complicating medical condition
Setting: laboratory
34 participants
18 male and 16 female
Mean age: 68 (SD 6.0)
Mean FEV1 (L): 0.88 (SD 0.3)
Mean baseline SaO2 (%): 92 (SD 5.2)
Mean baseline PaO2 (kPa): 7.7 (SD 1.5)
Mean baseline PaCO2 (kPa): no data available
Mean breathlessness at baseline: no data available
Interventions Oxygen (28% at 4 L/min) vs compressed air (4 L/min) before exercise. Gas was supplied
via constant performance masks, which supply 28% oxygen at the mouth over a wide
range of flow rates and breathing patterns
Outcomes Breathlessness measured by 100-mm VAS (“not breathless at all” to “the most breathless
I have ever been”)
HRQOL - no data available
Treatment preference - no data available
Adverse effects - no data available
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; information not
available
68Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Nandi 2003 (Continued)
Allocation concealment (selection bias) Unclear risk Information not available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “...neither the patient nor the test supervi-
sor was aware of the gas mixture being used,
or of oxygen saturation levels which were
recorded by another observer.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study.
Selective reporting (reporting bias) Low risk According to the aims, adequately reported
variables
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
Nonoyama 2007
Methods Randomised, controlled, double-blind (participants and study personnel), N-of-1 cross-
over trial
Participants Inclusion criteria: patients with a diagnosis of COPD (5) with dyspnoea limiting daily
activities, and with desaturation ≤ 88% for 2 continuous minutes during a room-air 6-
minute-walk test
Exclusion criteria: 18 years or younger; those who met criteria for mortality reduction
with long-term oxygen; those who received oxygen for palliative care or isolated nocturnal
hypoxaemia; those unable to complete the questionnaires or provide informed consent
Setting: home setting, Canada, outpatient
Method of recruitment of participants: Participants were recruited from local respiratory
rehabilitation programmes, respirology offices and home oxygen companies. The study
co-ordinator (MLN) was responsible for recruitment and enrolment
38 participants (27 completed)
Male 17 (63%)
Mean age: 69 (SD 10)
Lung function: no data available
Mean baseline SaO2 (%): no data available
Mean baseline PaO2 (kPa): no data available
Mean baseline PaO2 (kPa): no data available
Mean breathlessness at baseline: CRQ dyspnoea score 3.7 (SD 1.1)
Interventions Ambulatory oxygen (1-3 L/min) vs medical air (2 L/min) at exertion delivered through
nasal prongs by gas cylinders. Participants undertook 3 pairs of 2-week treatment periods.
Range of each period 9 to 21 days. Threshold for an adequate number of activities was
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set at 2 activities (chosen by participant), for a minimum duration of 1 hour a day
Outcomes Breathlessness measured by modified Borg (mBorg 0-10, 0 “none” to 10 “maximal”)
and CRQ dyspnoea domain 1-7 p
HRQOL - CRQ subdomains, SGRQ total score
Treatment preference - no data available
Adverse effects - number of dropouts
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Random allocation was
centralized; method of randomization was
computer generated.”
Allocation concealment (selection bias) Low risk “Allocation was concealed and the order
was randomly assigned to one of the eight
possible orders of the pairs of placebo and
active periods.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Oxygen and placebo gas in identical E-
sized and D-sized cylinders, marked only
with a code number indicating their con-
tents.”
“Patients and the outcome assessors were
blind to the gas mixture provided. This was
achieved by an independent person order-
ing, receiving and preparing the appropri-
ate cylinders and concentrator (oxygen or
placebo).”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data reported only for participants com-
pleting the study. High proportion of drop-
outs (11 dropouts in total)
Selective reporting (reporting bias) Low risk According to the aims, adequately reported
variables
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
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O’Donnell 1997
Methods Randomised, placebo-controlled, double-blinded (participant, investigators), cross-over
trial
Participants Inclusion criteria: advanced chronic airway limitation (FEV1 < 60% predicted); mild
hypoxaemia; did not meet criteria for LTOT; referred to an exercise programme because
sedentary; poor exercise tolerance; severe activity-related breathlessness
Exclusion criteria: clinical evidence of significant cardiovascular disease, other pul-
monary disease (including cor pulmonale) or other disorders that could contribute to
breathlessness or exercise limitation
Method for recruiting participants: Patients were referred to an exercise programme
because they were sedentary/had poor exercise tolerance/experienced severe activity-
related breathlessness
Setting: laboratory (Ontario, Canada)
11 participants
7 male and 4 female
Mean age: 68 (SEM 2)
Mean FEV1 (% predicted): 0.97 (SEM 0.13)
Mean FVC (% predicted): 2.3 (SEM 0.3)
Mean TLC (% predicted): 7.0 (SEM 0.5)
Mean RV (% predicted): 4.4 (SEM 0.3)
Mean DLCO (mL/min/mmHg): 8.8 (SEM 1.1)
Mean baseline SaO2 (%): no data available
Mean baseline PaO2 (kPa): 9.9 (SEM 0.4)
Mean baseline PaCO2 (kPa): 5.5 (SEM 0.3)
Mean breathlessness at baseline: 5.1 (SD 0.3)
Interventions Oxygen (FiO2 0.60) vs room air (FiO2 0.21) on endurance cycle exercise test. Participants
breathed through a mouthpiece and a low-resistance 2-way nonrebreathing valve with
the nose clipped
Outcomes Breathlessness measured by modified Borg (mBorg 0-10, 0 “none” to 10 “maximal”)
HRQOL - no data available
Treatment preference - no data available
Adverse effects - no data available
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; no other infor-
mation available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Subjects were blinded with respect to the
oxygen concentration being breathed, as
was the investigator evaluating subjective
responses and performing the data analysis;
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Identical breathing apparatus used in the
study.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As above
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study.
Selective reporting (reporting bias) Low risk According to the aims, adequately reported
variables
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
O’Driscoll 2011
Methods Randomised, controlled, single-blind (participants), cross-over trial
Participants Inclusion criteria: patients over 50 years of age; smoking history > 20 pack-years; severe
COPD with FEV1 < 40% of predicted; oxygen saturation at rest ≥ 93% breathing room
air at time of recruitment to study and on arrival on study day; breathless during modest
exercise such as climbing 1 or 2 flights of stairs; stable for 4 weeks (not requiring oral
steroids or antibiotics or both); able to give informed consent; able to undertake a simple
step test on an 18-cm exercise step
Exclusion criteria: unable or unwilling to give informed consent; unable or unwilling
to undertake step test for any reason; complicating comorbid conditions (e.g. arthritis of
knees) that might interfere with exercise test or with the conduct of the trial; and already
using oxygen at home
Setting: laboratory
Method of recruitment of participants: Participants were recruited from the chest clinic
or pulmonary rehabilitation service at Salford Royal University Hospital (UK)
39 participants (34 completed)
Male 24 (71%)
Mean age 69 (SD 10)
Mean FEV1 (L) 0.80 (SD 0.2)
Mean FEV1 (% predicted ) 31.4 (SD 5.5)
Mean baseline PaO2 (kPa): no data available
Mean baseline PaCO2 (kPa): no data available
Mean breathlessness at baseline: 1.5 (SD 1.1)
Interventions Oxygen (4 L/min) vs air (4 L/min) via face mask after exercise (step test)
Outcomes Breathlessness measured by modified Borg after step exercise test (mBorg 0-10, 0 “none”
to 10 “maximal”)
HRQOL - no data available
Treatment preference - categorical, at study end
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O’Driscoll 2011 (Continued)
Adverse effects - no data available
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients received one of the following in-
terventions in random order based on the
patient drawing four pieces of folded pa-
per sequentially from an opaque container
prior to the commencement of the exercise
task.”
Allocation concealment (selection bias) Low risk See above.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Single-blind. “The oxygen and air treat-
ments were single blind. To achieve blind-
ing for these two interventions, the investi-
gator connected a concealed air or oxygen
cylinder delivering a gas flow of 4 litres per
minute to the same face mask for each pa-
tient.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Breathlessness on a Borg scale reported
by participants; unclear whether they were
aware of saturation during, at the end of
exercise and during the recovery period.
The SpO2 and pulse rate were recorded in
the patient´ s trial record sheet each minute
during the exercise test, at the end of exer-
cise and every minute during recovery until
5 minutes after finishing the exercise task.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data reported only for participants com-
pleting the study. 5 dropouts in total
Selective reporting (reporting bias) Low risk According to the aims, adequately reported
variables
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
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Oliveira 2012a
Methods Randomised, controlled, double-blind (participants and study personnel), cross-over
trial
Participants Inclusion criteria: stable, non-hypercapnic (PaCO2 < 45 mmHg at rest) COPD; > 20
pack-years of smoking; resting saturation > 90% and PaO2 > 8 kPa; no evidence of
polycythemia or cor pulmonale. No participant had qualified previously for ambulatory
O2 therapy.
Exclusion criteria: recent exacerbation (within 1 month); treatment with oral corticos-
teroids; previous or current heart disease
Method of recruitment of participants: no data
Setting: laboratory (UK)
8 participants with COPD classified as “desaturators” with a drop in SaO2 and end-
exercise values < 88%
All male
Mean age: 66.7 (SD 7.9)
Mean FEV1 (L): 1.31 (SD 0.48)
Mean FEV1 (% predicted): 45.1 (SD 12.9)
Mean baseline SaO2 (%): no data available
Mean baseline PaO2 (kPa): 8.5 (SD 1.1)
Mean baseline PaCO2 (kPa): 5.2 (SD 0.6)
Mean breathlessness at baseline: no data available
Interventions Hyperoxia (FiO2 0.40) vs normoxia (FiO2 0.21) during incremental cycle tests; 2 tests ≥
2 days apart. Gas delivered through a facial mask connected to a low-resistance Douglas
bag
Outcomes Breathlessness measured by modified Borg at peak exercise (mBorg 0-10, 0 “none” to 10
“maximal”)
HRQOL - no data available
Treatment preference - no data available
Adverse effects - no data available
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Test sequence was randomised”; other In-
formation not available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Both patients and accompanying physi-
cian were blinded to the mixture being
breathed.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above.
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Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants
Selective reporting (reporting bias) Low risk According to the aims, adequately reported
variables
Other bias Low risk We judged that this trial appeared to be free
of other sources of bias
Oliveira 2012b
Methods Randomised, controlled, double-blind (participants and study personnel), cross-over
trial
Participants Inclusion criteria: stable, non-hypercapnic (PaCO2 < 45 mmHg at rest) COPD; > 20
pack-years of smoking; resting saturation > 90% and PaO2 > 8 kPa; no evidence of
polycythemia or cor pulmonale. No participant had qualified previously for ambulatory
O2 therapy.
Exclusion criteria: recent exacerbation (within 1 month), treatment with oral corticos-
teroids; previous or current heart disease
Method of recruitment of participants: no data
Setting: laboratory (UK)
12 participants classified as “non-desaturators”
All male
Mean age: 60.3 (SD 5.9)
Mean FEV1 (L): 1.56 (SD 0.41)
Mean FEV1 (% predicted): 48.6 (SD 10.8)
Mean baseline SaO2 (%): no data available
Mean baseline PaO2 (kPa): 10.0 (SD 1.3)
Mean baseline PaCO2 (kPa): 4.7 (SD 0.6)
Mean breathlessness at baseline: no data available
Interventions Hyperoxia (FiO2 0.40) vs normoxia (FiO2 0.21) during incremental cycle tests; 2 tests
≥ 2 days apart. Gas delivered through facial mask connected to a low-resistance Douglas
bag
Outcomes Breathlessness measured by modified Borg at peak exercise (mBorg 0-10, 0 “none” to 10
“maximal”)
HRQOL - no data available
Treatment preference - no data available
Adverse effects - no data available
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk “Test sequence was randomised”; other In-
formation not available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Both patients and accompanying physi-
cian were blinded to the mixture being
breathed.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study.
Selective reporting (reporting bias) Low risk According to the aims, adequately reported
variables
Other bias Low risk We judged that this trial appeared to be free
of other sources of bias
Ringbaek 2013
Methods Randomised, controlled, single-blinded (participants), parallel-group trial
Participants Inclusion criteria: stable COPD (FEV1 < 80% of predicted and FEV1/FVC < 0.70);
breathlessness with MRC score 3-5; motivated for PR; oxygen saturation at rest > 90%;
desaturation > 4% and < 90% during ISWT or ESWT
Exclusion criteria: LTOT; significant musculoskeletal, cardiac or cognitive problems
Method of recruitment of participants: Of 391 participants starting PR at the centre
between March 2007 and March
2011, 163 eligible patients were encouraged to participate in this trial
Setting: ambulatory rehabilitation training (Denmark)
45 participants
Male 53.3%
Mean age: 69.0 (SD 8.7)
Mean FEV1 (% predicted): 31.8 (SD 13.8)
Mean baseline SaO2 (%): 94 (SD 2.0)
Mean baseline PaO2 (kPa): no data available
Mean baseline PaCO2 (kPa): no data available
Mean breathlessness at baseline, MRC (min-max): oxygen 4.7 (3-5); controls 4.3 (3-5)
Interventions Ambulatory oxygen (2 L/min) vs control (no ambulatory oxygen); oxygen delivered
through a 2.3-kg portable oxygen concentrator. Participants were asked to use oxygen
during supervised and unsupervised exercise (≥ 30 min/d) for up to 33 weeks
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Outcomes Breathlessness measured by modified Borg after 7 weeks of training (mBorg 0-10, 0
“none” to 10 “maximal”)
HRQL - SGRQ total score
Treatment preference - no data available
Adverse effects - COPD exacerbations, all hospital admissions, deaths at study end
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Were randomised to either ambulatory
oxygen (AO) (n=22) or to a control group
(n=23) in blocks of 6, using sealed en-
velopes.” Other information not available
Allocation concealment (selection bias) Low risk Sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “without use of a sham concentrator”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk See above.
Incomplete outcome data (attrition bias)
All outcomes
High risk Data reported only for participants com-
pleting the study. High and unequal pro-
portion of dropouts (7 missing for inter-
vention; only 1 for comparison). “Baseline
and week 7 only in the analysis”
Selective reporting (reporting bias) Low risk Have protocol and IPD data
Other bias Low risk We judged that this trial appeared to be free
of other sources of bias
Rooyackers 1997
Methods Randomised, controlled, unblinded, parallel-group trial
Participants Inclusion criteria: hypoxaemia (SaO2 < 90%) at maximal exercise; increase in alveolar-
arterial difference in oxygen tension ≥ 2 kPa from rest to maximal incremental exercise
test; former smoker
Exclusion criteria: resting PaO2 < 64 mmHg; mean nocturnal SaO2 < 90%; mean
pulmonary artery pressure > 25 mmHg measured at rest by Doppler echocardiography;
neuromuscular or cardiovascular disease; any medication change during the study
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Setting: laboratory
Method for recruitment of participants: Patients were referred to the hospital for PR
(Dekkerswald, Netherlands)
24 participants in total
12 participants allocated to 10 weeks of general exercise training breathing room air; “air
group”
12 participants allocated to supplemental oxygen (4 L/min) during general exercise
training for 10 weeks; “oxygen group”
10 male and 2 female in each group
See Rooyackers 1997a; Rooyackers 1997b for baseline characteristics and resting pul-
monary function data
Interventions See Rooyackers 1997a; Rooyackers 1997b.
Outcomes HRQOL - CRQ total score (higher = better QoL), CRQ subdomains
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information available
Allocation concealment (selection bias) Unclear risk “The patients were randomly allocated
either to general exercise training while
breathing room air or while breathing
at a flow rate of 4 L·min-1 through a dual-
prong nasal cannula.” No other informa-
tion available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk While performing the tests: “During oxy-
gen breathing, it was not possible to mea-
sure V’O2, and blood gas analysis was not
performed.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk As above
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study.
Selective reporting (reporting bias) Low risk According to the aims, adequately reported
variables
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
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Methods Randomised, controlled, unblinded, parallel-group trial
Participants Inclusion criteria: hypoxaemia (SaO2 < 90%) at maximal exercise; increase in alveolar-
arterial difference in oxygen tension ≥ 2 kPa from rest to maximal incremental exercise
test; former smoker
Exclusion criteria: resting PaO2 < 64 mmHg; mean nocturnal SaO2 < 90%, mean
pulmonary artery pressure > 25 mmHg measured at rest by Doppler echocardiography;
neuromuscular or cardiovascular disease; any medication change during the study
Setting: laboratory
Method for recruitment of participants: Patients were referred to the hospital for PR
(Dekkerswald, Netherlands)
12 participants allocated to 10 weeks of general exercise training breathing room air; “air
group”
10 male and 2 female
Mean age: 59 (SD 13)
Mean FEV1 (L): 1.2 (SD 0.5)
Mean TLC (% predicted): 114 (SD 20)
Mean baseline SaO2 (%): no data available
Mean baseline PaO2 (kPa): 10.5 (SD 1.1)
Mean baseline PaCO2 (kPa): 5.0 (SD 0.8)
Mean breathlessness at baseline: no data available
Interventions Room air (RA) vs oxygen (4 L/min) during maximal incremental cycle exercise test,
single-stage exercise test and 6MWT
Outcomes Breathlessness measured by modified Borg (mBorg 0-10, 0 “none” to 10 “maximal”)
HRQOL - CRQ total score (higher = better QoL), CRQ subdomains
Treatment preference - no data available
Adverse effects - no data available
Notes In both groups, the work rate was not allowed to exceed the level at which SaO2 fell
below 90%.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information available
Allocation concealment (selection bias) Unclear risk “The patients were randomly allocated
either to general exercise training while
breathing room air or while breathing sup-
plemental oxygen at a flow rate of 4 L·min-
1 through a dual-prong nasal cannula.” No
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other information available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk While performing the tests: “During oxy-
gen breathing, it was not possible to mea-
sure V’O2, and blood gas analysis was not
performed.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk As above
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study.
Selective reporting (reporting bias) Low risk According to the aims, adequately reported
variables
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
Rooyackers 1997b
Methods Randomised, controlled, unblinded, parallel-group trial
Participants Inclusion criteria: hypoxaemia (SaO2 < 90%) at maximal exercise and increase in alve-
olar-arterial difference in oxygen tension ≥ 2 kPa from rest to maximal exercise during
maximal incremental exercise; former smoker; no medication changes during the study
Exclusion criteria: resting PaO2 < 64 mmHg, mean nocturnal SaO2 < 90%, mean
pulmonary artery pressure > 25 mmHg measured at rest by Doppler echocardiography;
neuromuscular or cardiovascular disorder
Setting: laboratory
Method for recruitment of participants: Patients were referred to the hospital for PR
(Dekkerswald, Netherlands)
12 participants allocated to supplemental oxygen (4 L/min) during general exercise
training for 10 weeks; “oxygen group”
10 male and 2 female
Mean age: 63 (SD 5)
Mean FEV1 (L): 0.9 (SD 0.3)
Mean TLC (% predicted): 109 (SD 17)
Mean baseline SaO2 (%): no data available
Mean baseline PaO2 (kPa): 10.2 (SD 1.6)
Mean baseline PaCO2 (kPa): 5.1 (SD 1.1)
Mean breathlessness at baseline: no data available
Interventions Oxygen (4 L/min) vs room air (RA) during maximal incremental cycle exercise test,
single-stage exercise test and 6MWT
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Outcomes Breathlessness measured by modified Borg (mBorg 0-10, 0 “none” to 10 “maximal”)
HRQOL - CRQ total score (higher = better QoL), CRQ subdomains
Treatment preference - no data available
Adverse effects - no data available
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information available
Allocation concealment (selection bias) Unclear risk “The patients were randomly allocated
either to general exercise training while
breathing room air or while breathing sup-
plemental oxygen at a flow rate of 4 L·min-
1 through a dual-prong nasal cannula.” No
other information available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk While performing the tests: “During oxy-
gen breathing, it was not possible to mea-
sure V’O2, and blood gas analysis was not
performed.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk As above
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study.
Selective reporting (reporting bias) Low risk According to the aims, adequately reported
variables
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
Scorsone 2010
Methods Randomised, controlled, double-blind (participants and study personnel), parallel-group
trial
Participants Inclusion criteria: clinical diagnosis of COPD and airflow obstruction confirmed by
spirometry; although not stated as criteria, all participants had a history of smoking and
were under regular bronchodilator treatment
Exclusion criteria: not stated
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Method of recruitment of participants: not stated
Setting: pulmonary rehab programme (Italy)
20 participants
Male 14 (70%)
Mean age: air 68 (SD 7); oxygen 67 (SD 9)
Mean FEV1/FVC: air 47 (SD 12); oxygen 51 (SD 8)
Mean FEV1 (% predicted): air 50 (SD 12); oxygen 47 (SD 10)
Mean baseline SaO2 (%): no data available
Mean baseline PaO2 (kPa): oxygen 9.9 (SD 1.0); air 10.2 (SD 1.2)
Mean baseline PaCO2 (kPa): oxygen 5.3 (SD 0.4); air 5.1 (SD 0.4)
Mean breathlessness at baseline: oxygen 7 (SD 3); air 7 (SD 3)
Interventions Supplemental oxygen (FiO2 0.4) vs air delivered by mouthpiece from a Douglas bag; an
8-week, 3 times a week training programme conducted on a calibrated cycle ergometer
Outcomes Breathlessness measured by modified Borg at isotime of exertion (mBorg 0-10, 0 “none”
to 10 “maximal”)
HRQOL - no data available
Treatment preference - no data available
Adverse effects - no data available
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; other informa-
tion not available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “PaO2 saturation was continuously moni-
tored by a technician blind to the design of
the study.”
“.. according to a randomised, double-
blind design in which subjects breathed hu-
midified air, supplemental O2 40%, or he-
liox 60:40 at random through a mouth-
piece from a Douglas bag”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study.
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Selective reporting (reporting bias) Low risk According to the aims, adequately reported
variables
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
Somfay 2001
Methods Randomised, controlled, single-blind (participants), cross-over trial
Participants Inclusion criteria: severe COPD (FEV1 < 40% predicted); no more than mildly hypox-
aemic (O2 sat at rest > 92% and during exercise > 88%); none had previously qualified
for home oxygen
Exclusion criteria: clinically manifest cor pulmonale; severe cardiovascular comorbidity
or other disease that might contribute to breathlessness or exercise limitation
10 participants
Setting: laboratory
6 male and 4 female
Mean age: 67 (SD 7)
Mean FEV1 (L): 0.92 (SD 0.43)
Mean FVC (% predicted): 76 (SD 15)
Mean TLC (L): 7.3 (SD 1.5)
Mean RV (L): 4.3 (SD 1.3)
Mean baseline SaO2 (%): 96 (SD 0.8)
Mean baseline PaO2 (kPa): no data available
Mean baseline PaCO2 (kPa): no data available
Mean breathlessness at baseline: no data available
Interventions Oxygen (30%, 50%, 75% or 100%) vs compressed air during constant work rate test
at 75% of peak work rate. Compressed air and oxygen were blended from gas cylinders
into a 200-L meteorological balloon to be inspired during exercise. Participants breathed
through a mouthpiece attached to a low-resistance, 2-way, nonrebreathing valve
Outcomes Breathlessness measured by modified Borg (mBorg 0-10, 0 “none” to 10 “maximal”)
HRQOL - no data available
Treatment preference - no data available
Adverse effects - no data available
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; no other infor-
mation available
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Allocation concealment (selection bias) Unclear risk Information not available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Single-blind study; “Subjects were blinded
with respect to the oxygen concentration
they breathed.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk As above
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study.
Selective reporting (reporting bias) Low risk Adequately reported variables
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
Spielmanns 2014
Methods Randomised, controlled, parallel-group trial
Participants Inclusion criteria: diagnosis of COPD and FEV1/FVC < 0.7 after bronchodilation;
FEV1 < 80% of predicted; stable clinical condition for ≥ 4 weeks; normoxaemia (SaO2
> 90%) at rest and during exercise without oxygen supply
Exclusion criteria: comorbidity that could interfere with training, such as ischaemic
cardiac disease, musculoskeletal problems and psychological disorders
Method of recruitment of participants: invited to take part when referred by general
practitioners to the St Remigius Hospital, in Leverkusen, Germany, from September
2009 to March 2011
Setting: 1 outpatient pulmonary rehabilitation programme (St Remigius Hospital, Lev-
erkusen, Germany)
85 participants with COPD (39 withdrawals; 18 oxygen group; 21 medical air)
No data on sex
Mean age: oxygen 65 (SD 8.7); air 64 (SD 8.4)
Mean FEV1 (L): oxygen 1.2 (SD 0.5); air 1.5 (SD 0.4)
Mean FEV1 (% predicted): oxygen 44 (SD 10); air 43 (SD 12)
Mean baseline SaO2 (%): > 90% according to inclusion criteria
Mean baseline PaO2 (kPa): no data available
Mean baseline PaCO2 (kPa): no data available
Mean breathlessness at baseline: no data available
Interventions Oxygen (4 L/min) vs compressed air (4 L/min) during training cycle tests delivered via
nasal cannula. Duration of treatment: training sessions throughout 24 weeks; 3 sessions/
wk
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Outcomes Breathlessness - no data available
HRQL - SF-36; subscores with range from 0 to 100; measured at baseline and after 12
weeks
Treatment preference - no data available
Adverse effects - number of dropouts
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization scheme was generated
using the website Randomization.com us-
ing a computer-generated list of random
numbers to assign subjects to either the
oxygen or compressed air group.”
Allocation concealment (selection bias) Low risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not sufficient information. “Tests were
conducted by an unblinded coach; the sub-
jects and investigator were not aware of the
group to which they belonged until the end
of all experiments.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk As above
Incomplete outcome data (attrition bias)
All outcomes
High risk Data reported only for participants com-
pleting the study. High proportion of drop-
outs (39 in total; 18 from oxygen group;
21 from medical air)
Selective reporting (reporting bias) Low risk Adequately reported variables
Other bias Low risk We judged that this trial appeared to be free
of other sources of bias
Swinburn 1984
Methods Randomised, single-blinded (participants), cross-over trial
Participants Inclusion criteria: advanced obstructive airways disease but in “stable clinical state”
Exclusion criteria: not stated
Setting: laboratory
5 participants
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Swinburn 1984 (Continued)
Mean age: 65 (range 53-72)
Mean FEV1 (L): 0.8 (SD 0.2)
Mean FVC (L): 1.8 (SD 0.4)
Mean baseline SaO2 (%): 93.2 (SD 0.8)
Mean baseline PaO2 (kPa): no data available
Mean baseline PaCO2 (kPa): no data available
Mean breathlessness at baseline: no data available
Interventions Room air (RA) vs oxygen (60%) delivered through a mouthpiece during incremental
cycle exercise test
Outcomes Breathlessness measured by 10-cm VAS scale (“minimum” to “maximum”)
HRQOL - no data available
Treatment preference - no data available
Adverse effects - no data available
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; other informa-
tion not available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Single-blind. “The patients were informed
that the purpose of the study was to inves-
tigate the effects of different gas mixtures
on exercise performance.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Information not available
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study.
Selective reporting (reporting bias) Low risk Adequately reported outcomes
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
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Voduc 2010
Methods Randomised, controlled, double-blind (participants and study personnel), cross-over
trial
Participants Inclusion criteria: clinically stable COPD; accepted into the pulmonary rehabilitation
programme; clinical diagnosis of COPD; FEV1/FVC < 0.7; FEV1 < 70% of predicted
Exclusion criteria: hypoxia (SaO2 < 89%) at rest or during ambulation; non-pulmonary
conditions that could affect exercise performance (e.g. angina, congestive heart fail-
ure, severe musculoskeletal problems) or lung diseases other than COPD (e.g. asthma,
bronchiectasis); and recent COPD exacerbations or changes in regular medications
within the past 2 months
Method of recruitment of participants: All patients were initially referred for pulmonary
rehabilitation for improvement of exertional dyspnoea that was not satisfactorily man-
aged by pharmacological therapy alone
Setting: 1 rehabilitation programme (Ottawa, Ontario, Canada)
24 participants (16 completed)
Male 14 (70%)
Mean age: 65.9 (SD 6.6)
Mean FEV1/FVC: 41.5 (SD 13.8)
Mean baseline SaO2 (%): 97 (SD 1.9)
Mean baseline PaO2 (kPa): no data available
Mean baseline PaCO2 (kPa): no data available
Mean breathlessness at baseline: no data available
Interventions Oxygen (FiO2 0.5) vs room air delivered through a mask connected to a Douglas bag
during 2 symptom-limited constant-load exercise tests
Outcomes Breathlessness measured by modified Borg at isotime (mBorg 0-10, 0 “none” to 10
“maximal”)
HRQOL - no data available
Treatment preference - no data available
Adverse effects - number of dropouts
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The order of testing was randomised.”
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Both the patient and the supervising
physician were blinded to the nature of the
inhaled gas.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above.
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Voduc 2010 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Included only participants who completed
the whole 12-week training period. In total,
8 dropouts. They could have had a different
acute response to oxygen
Selective reporting (reporting bias) Low risk Adequately reported variables
Other bias Unclear risk It is unclear whether or not there was risk
of other bias due to the lack of detail in the
methods
Wadell 2001
Methods Randomised, controlled, single-blind (participants), parallel-group trial
Participants Inclusion criteria: age < 75 years; stopped smoking ≥ 6 months before entering the
study; PaO2 > 60 mmHg at rest; hypoxaemia (SaO2 ≤ 92%) during exercise (6MWT
test); FEV1 < 70% of predicted; no infection in the 3 weeks preceding study enrolment;
no change in medical treatment in the month preceding enrolment
Exclusion criteria: past or present major illness, such as cardiac, orthopaedic or neuro-
logical disease that might have interfered with exercise performance
Setting: laboratory
Method of recruiting participants: recruited from previously diagnosed outpatients who
had been treated at the Department of Respiratory Medicine and Allergy at the University
Hospital in Umea, Sweden
22 participants (20 completed)
10 in air group and 10 in oxygen group
Median age: air 69 (60 to 72); oxygen 65 (52 to 73)
Median FEV1 (% predicted): air 51.6 (24 to 66); oxygen 39.3 (23 to 59)
Median baseline SaO2 (%): air 95 (91 to 97); oxygen 95 (93-97)
Median baseline PaO2 (kPa): air 9.3 (7.9 to 11.4); oxygen 9.5 (8.6 to 11.6)
Median baseline PaCO2 (kPa): 9.3 (7.9 to 11.4); oxygen 5.4 (4.5 to 5.8)
Median breathlessness at baseline: 1.5 (0 to 3)
Interventions Oxygen (5 L/min) vs air (5 L/min) delivered through a dual-prong nasal cannula during
6MWT on treadmill - baseline effect of 2 interventions, as complete study involved
training over an 8-week period
Outcomes Breathlessness measured by modified Borg (mBorg 0-10, 0 “none” to 10 “maximal”)
HRQOL - no data available
Treatment preference - no data available
Adverse effects - no data available
Notes The treadmill was stopped if participants rated 7/17 (respectively) or more on Borg scales
and/or if participants’ SaO2 fell below 90%.
Risk of bias
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Wadell 2001 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The included patients were randomly al-
located (randomization by blocks, men
and women were randomised separately) to
train either with air (AG) or with oxygen
(OG).”
Allocation concealment (selection bias) Unclear risk Not enough information available to deter-
mine how order of treatment group assign-
ment was concealed from investigators
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Single-blind study”; “SaO2 and heart rate
were continuously monitored with a pulse
oximeter using a finger probe or a forehead
probe.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcomes self-reported by participant
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data reported only for participants com-
pleting the study (2 withdrawals)
Selective reporting (reporting bias) Low risk Adequately reported variables
Other bias Low risk We judged that this trial appeared to be free
of other sources of bias
Woodcock 1981
Methods Randomised, double-blind (participants and study personnel), cross-over trial
Participants Inclusion criteria: fixed airways obstruction; “moderate or severe breathlessness on
exertion” (method of defining not stated); normal or low PaO2
Exclusion criteria: none stated
Setting: laboratory
10 participants
9 male and 1 female
Mean age: 62 (range 43-70)
Mean FEV1 (L): 0.71 (SD 0.29)
Mean FVC (L): 2.65 (SD 1.04)
Mean baseline SaO2 (%): no data available
Mean baseline PaO2 (kPa): 9.6 (SD 1.5)
Mean baseline PaCO2 (kPa): 4.6 (SD 0.6)
Mean breathlessness at baseline: 4 (SD 0.94)
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Woodcock 1981 (Continued)
Interventions Oxygen (described as 100% delivered at 4 L/min) vs compressed air (4 L/min) during
treadmill test and 6MWT
Outcomes Breathlessness measured by 10-cm VAS
HRQOL - no data available
Treatment preference - no data available
Adverse effects - no data available
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; other informa-
tion not available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Compressed air versus oxygen delivered
via coded unmarked cylinders”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study.
Selective reporting (reporting bias) Low risk Adequately reported outcomes
Other bias Low risk We judged that this trial appeared to be free
of other sources of bias
6MWT: six-minute walk test; AAT: alpha-1 antitrypsin; ABG: arterial blood gas; ATS: American Thoracic Society; BTS: British
Thoracic Society; CA: compressed air; CAD: coronary artery disease; CO: carbon monoxide; COPD: chronic obstructive pulmonary
disease; CPET: cardiopulmonary exercise testing; CRQ: Chronic Respiratory Questionnaire; DLCO: diffusing capacity of the
lung for carbon monoxide; ESWT: endurance shuttle walk test; FEV1: forced expiratory volume in one second; FiO2: fraction of
inspired oxygen; FVC: forced vital capacity; HR: heart rate; HRQOL: health-related quality of life; IPD: individual patient data;
IQR: interquartile range; ISWT: incremental shuttle walk test; LTOT: long-term oxygen relief therapy; PaCO2: partial pressure of
carbon dioxide in arterial blood; PaO2: partial pressure of oxygen in arterial blood; PCO2: partial pressure of carbon dioxide; PFT:
pulmonary function test; PO2: partial pressure of oxygen; PR: pulmonary rehabilitation; RA: room air; RV: right ventricle; SaO2:
oxygen saturation; SBOT: short-burst oxygen therapy; SD: standard deviation; SEM: standard error of the mean; SF-36: Short Form
36; SGRQ: St George’s Respiratory Quotient; SMD: standard mean difference; SpO2: oxygen saturation; TLC: total lung capacity;
TR: tricuspid regurgitation; VAS: visual analogue scale; VC: vital capacity.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alexandre 2010 Other - abstract, no suitable outcome
Arnold 2008 Other - abstract
Balkissoon 2006 Other - review of another manuscript
Bjørgen 2009 No suitable outcome
Bradley 1978 No suitable outcome
Bye 1985 No suitable outcome
Campbell 2013 Patients already receiving home oxygen
Caspersen 2012 Other - abstract
Criner 1987 No suitable outcome
Cuvelier 2002 Patients already receiving home oxygen
Edvardsen 2007 Patients already receiving home oxygen
Evans 1986 No suitable outcome
Fraser 2013 Patients already receiving home oxygen
Fujimoto 2002 No suitable outcome
Garrod 2000 Patients already receiving home oxygen
Gosselin 2004 No suitable outcome
Heinzelmann 2011 Other - abstract
Helgerud 2010 No suitable outcome
King 1973 Mean PaO2 < 55 mmHg
King 2012 Other - abstract
Lane 1987 Not a randomised controlled trial
Leggett 1977 Mean PaO2 < 55 mmHg
No suitable outcome
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(Continued)
Lellouche 2011 Other - abstract
Light 1989 No suitable outcome
Liss 1988 Patients already receiving home oxygen
Lock 1992 Mean PaO2 < 55 mmHg
No placebo or control arm
Maldonado 2014 Mean PaO2 < 55 mmHg; study performed at Bogota altitude
Mannix 1992 No suitable outcome
Marques-Magallanes 1998 Mean PaO2 < 55 mmHg
No suitable outcome
Matsuzawa Japanese with no capacity for translation
Nasilowski 2008 Patients already receiving home oxygen
Nguyen 2008 Intervention not oxygen vs medical air
Noseda 1997 Intervention not oxygen vs medical air
O’Donnell 2001 Patients already receiving home oxygen
O’Driscoll 2003 Other - editorial
O’Driscoll 2007 No suitable outcome
O’Neill 2006 No suitable outcome
Ouyang 2006 Intervention not oxygen vs medical air
Palwai 2010 Patients already receiving home oxygen
Peters 2006 Intervention not oxygen vs medical air
Raimondi 1970 No suitable outcome
Roberts 1996 Mean PaO2 < 55 mmHg
Patients already receiving home oxygen
Sandland 2008a Patients hypoxic at rest
Sandland 2008b Patients already receiving home oxygen or PRN oxygen
No dyspnoea outcome
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(Continued)
Sforza 2010 Other - abstract
Stein 1982 No suitable outcome
Stevenson 2004 No suitable outcome
Swinburn 1991 Mean PaO2 < 55 mmHg
Vyas 1971 No suitable outcome
Waterhouse 1983 No suitable outcome
Wedzicha 2006 Other - editorial
Womble 2010 Other - abstract
Womble 2012 No suitable outcome
PaO2: partial pressure of oxygen in arterial blood; PRN: pro re nata, or ’as needed’.
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D A T A A N D A N A L Y S E S
Comparison 1. Oxygen versus air




participants Statistical method Effect size
1 Breathlessness - all trials 32 Std. Mean Difference (Random, 95% CI) -0.31 [-0.43, -0.20]
2 Breathlessness - subgroup
analysis - short-burst oxygen vs
not
32 SMD (Random, 95% CI) Subtotals only
2.1 Studies using short-burst
oxygen
4 SMD (Random, 95% CI) -0.03 [-0.28, 0.22]
2.2 Studies not using short-
burst oxygen
28 SMD (Random, 95% CI) -0.36 [-0.48, -0.24]
3 Breathlessness - subgroup
analysis - exertional
desaturation vs not
31 SMD (Random, 95% CI) Subtotals only
3.1 Studies with exertional
desaturation
16 SMD (Random, 95% CI) -0.28 [-0.39, -0.16]
3.2 Studies with no exertional
desaturation
15 SMD (Random, 95% CI) -0.47 [-0.69, -0.24]
4 Breathlessness - subgroup
analysis - mean PaO2 < 9.3 kPa
vs higher
32 SMD (Random, 95% CI) Subtotals only
4.1 Studies with mean PaO2 <
9.3 kPa
7 SMD (Random, 95% CI) -0.28 [-0.48, -0.07]
4.2 Studies with mean PaO2
≥ 9.3 kPa
25 SMD (Random, 95% CI) -0.33 [-0.47, -0.20]
5 Breathlessness - subgroup
analysis - measured during
exercise test vs not
32 SMD (Random, 95% CI) -0.31 [-0.43, -0.20]
5.1 Studies measuring during
exercise test
30 SMD (Random, 95% CI) -0.34 [-0.46, -0.22]
5.2 Studies not measuring
during exercise test
2 SMD (Random, 95% CI) -0.13 [-0.37, 0.11]
6 Breathlessness - subgroup
analysis - laboratory vs other
32 SMD (Random, 95% CI) -0.31 [-0.43, -0.20]
6.1 Studies in laboratory
setting
25 SMD (Random, 95% CI) -0.37 [-0.52, -0.22]
6.2 Studies in non-laboratory
setting
7 SMD (Random, 95% CI) -0.23 [-0.36, -0.09]
7 Breathlessness - subgroup
analysis - short-term vs long-
term (training) effect of oxygen
32 Std. Mean Difference (Random, 95% CI) -0.31 [-0.43, -0.20]
7.1 Studies of short-term
effect of oxygen
29 Std. Mean Difference (Random, 95% CI) -0.34 [-0.46, -0.22]
7.2 Studies of long-term effect
of oxygen
3 Std. Mean Difference (Random, 95% CI) -0.09 [-0.37, 0.19]
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8 Breathlessness - subgroup
analysis - mean oxygen dose >
2 L/min vs lower
30 Std. Mean Difference (Random, 95% CI) -0.31 [-0.43, -0.18]
8.1 Studies with a mean
oxygen dose > 2 L/min
26 Std. Mean Difference (Random, 95% CI) -0.35 [-0.49, -0.21]
8.2 Studies with a mean
oxygen dose ≤ 2 L/min
5 Std. Mean Difference (Random, 95% CI) -0.19 [-0.39, 0.01]
9 Breathlessness - sensitivity
analysis - excluding
measurements at peak exertion
26 Std. Mean Difference (Random, 95% CI) -0.37 [-0.50, -0.24]
10 Breathlessness - sensitivity
analysis - excluding studies
with high risk of bias
25 SMD (Random, 95% CI) -0.30 [-0.41, -0.20]
11 Breathlessness - sensitivity
analysis - excluding outliers
26 Std. Mean Difference (Random, 95% CI) -0.27 [-0.35, -0.18]
12 Breathlessness - sensitivity
analysis - post hoc - excluding
short-burst and outliers
22 SMD (Random, 95% CI) -0.30 [-0.39, -0.20]
13 Health-related quality of life -
all trials
5 Std. Mean Difference (Random, 95% CI) 0.12 [-0.04, 0.28]
A D D I T I O N A L T A B L E S
Table 1. Characteristics of included trials
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NA 7 (SD 3) Modified
Borg
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NC 4 L/min 9.6 (SD
1.5)





CRQ: Chronic Respiratory Questionnaire; NA: not available; NC: nasal cannula; SD: standard deviation; SE: standard error; SF-36:
Short Form-36 questionnaire; VAS: visual analogue scale.
Data presented as mean (standard deviation (SD)) unless otherwise specified.
aAs measured by dyspnoea index.
bAs measured by MRC dyspnoea grade.
W H A T ’ S N E W
Last assessed as up-to-date: 12 July 2016.
Date Event Description
12 July 2016 New search has been performed The systematic search, review and meta-analysis have been
updated to 12 July 2016
12 July 2016 New citation required and conclusions have changed This review update added14 studies including 493 partici-
pants to the review. With the addition of these studies, the
precision of the main analyses has been improved. Several
new subanalyses have been performed, including level of de-
saturation during exercise, setting (laboratory or daily life)
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(Continued)
, short-term versus long-term effects, type of measurement
(iso-time or maximal exertion) and oxygen dose. We graded
the quality of evidence and were able to meta-analyse data
for health-related quality of life
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D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
After statistical review, we included only post scores and not change scores in the meta-analyses, so as not to compare SMDs on the
same scale. We also added a post hoc sensitivity analysis of breathlessness that excluded outliers and short-burst oxygen therapy.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Dyspnea [etiology; ∗therapy]; Exercise; Health Status; Home Care Services; Oxygen Inhalation Therapy [∗methods]; Pulmonary
Disease, Chronic Obstructive [complications; ∗therapy]; Quality of Life; Randomized Controlled Trials as Topic
MeSH check words
Humans
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